Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Novel CFTR modulators correct trafficking defects and enhance ion transport in cystic fibrosis by increasing the functional presence of CFTR channels, addressing the limitations of current treatments and improving patient outcomes.
Patent Information
- Application Number
- CA3046086
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-12-09
- Filing Date
- 2017-12-08
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2037-12-08
AI Technical Summary
Current treatments for cystic fibrosis (CF) are inadequate, as they fail to address the reduced anion transport and defective channel gating caused by mutations in the CFTR protein, leading to severe respiratory and gastrointestinal issues, infertility, and reduced fertility in affected individuals.
Development of novel compounds, including CFTR modulators such as Formulae (I)-(VI) and their pharmaceutically acceptable salts, which act as CFTR correctors and potentiators to enhance the activity and trafficking of the CFTR protein, thereby improving anion and fluid transport across epithelial cells.
The CFTR modulators increase the functional presence of CFTR channels at the cell surface, correcting trafficking defects and enhancing ion transport, thus alleviating symptoms of cystic fibrosis and improving the quality of life for patients.
Abstract
Description
Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator
[0001] Disclosed herein is a modulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing the modulator, methods of treatment of cystic fibrosis, and a process for making the modulator.
[0002] Cystic fibrosis (CF) is a recessive genetic disease that affects approximately 70,000 children and adults worldwide. Despite progress in the treatment of CF, there is no cure.
[0003] In patients with CF, mutations in CFTR endogenously expressed in respiratory epithelia lead to reduced apical anion secretion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and accompanying microbial infections that ultimately cause death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, result in death. In addition, the majority of males with cystic fibrosis are infertile, and fertility is reduced among females with cystic fibrosis.
[0004] Sequence analysis of the CFTR gene has revealed a variety of disease causing mutations (Cutting, G. R. et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, B-S. et al. (1989) Science 245:1073-1080; Kerem, B-S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, greater than 2000 mutations in the CF gene have been identified; currently, the CFTR2 database contains information on only 322 of these identified mutations, with sufficient evidence to define 281 mutations as disease causing. The most prevalent disease-causing mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as the F508del mutation. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with severe disease.
[0005] The deletion of residue 508 in CFTR prevents the nascent protein from folding correctly. This results in the inability of the mutant protein to exit the endoplasmic reticulum (ER) and traffic to the plasma membrane. As a result, the number of CFTR channels for anion transport present in the membrane is far less than observed in cells expressing wild-type CFTR, i.e., CFTR having no mutations. In addition to impaired trafficking, the mutation results in defective channel gating. Together, the reduced number of channels in the membrane and the defective gating lead to reduced anion and fluid transport across epithelia. (Quinton, P. M. (1990), FASEB J. 4: 2709-2727). The channels that are defective because of the F508del mutation are still functional, albeit less functional than wild-type CFTR channels. (Dalemans et al. (1991), Nature Lond. 354: 526-528; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to F508del, other disease causing mutations in CFTR that result in defective trafficking, synthesis, and / or channel gating could be up- or down-regulated to alter anion secretion and modify disease progression and / or severity.
[0006] CFTR is a cAMP / ATP-mediated anion channel that is expressed in a variety of cell types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelial cells, normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue. CFTR is composed of approximately 1480 amino acids that encode a protein which is made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
[0007] Chloride transport takes place by the coordinated activity of ENaC and CFTR present on the apical membrane and the Na<com:Sup>+< / com:Sup>-K<com:Sup>+< / com:Sup>-ATPase pump and Cl- channels expressed on the basolateral surface of the cell. Secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which can then passively leave the cell via Cl<com:Sup>-< / com:Sup> channels, resulting in a vectorial transport. Arrangement of Na<com:Sup>+< / com:Sup> / 2Cl<com:Sup>-< / com:Sup> / K<com:Sup>+< / com:Sup> co-transporter, Na<com:Sup>+< / com:Sup>-K<com:Sup>+< / com:Sup>-ATPase pump and the basolateral membrane K<com:Sup>+< / com:Sup> channels on the basolateral surface and CFTR on the luminal side coordinate the secretion of chloride via CFTR on the luminal side. Because water is probably never actively transported itself, its flow across epithelia depends on tiny transepithelial osmotic gradients generated by the bulk flow of sodium and chloride.
[0008] Accordingly, there is a need for novel treatments of CFTR mediated diseases.
[0009] Disclosed herein are novel compounds, including compounds of Formulae (I)-(VI) and pharmaceutically acceptable salts thereof. For example, compounds of Formula (I) can be depicted as: [Image disponible dans le document PDF, Image available in the PDF document] (I), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; - <com:Math><semantics>X<annotation encoding="application / x-tex">X< / annotation>< / semantics>< / com:Math> is chosen from O, NH, and N(C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl) groups; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from halogens, cyano, hydroxy, hydroxymethyl, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen; halogens; cyano; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy; and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8.
[0010] Also disclosed herein are pharmaceutical compositions comprising at least one of the novel compounds disclosed herein and / or at least one pharmaceutically acceptable salt thereof, which compositions may further include at least one additional active pharmaceutical ingredient and / or at least one carrier. Also disclosed are methods of treating the CFTR-mediated disease cystic fibrosis comprising administering at least one of the novel compounds disclosed herein and / or at least one pharmaceutically acceptable salt thereof, optionally as part of a pharmaceutical composition comprising at least one additional component, to a subject in need thereof.
[0011] Also disclosed are methods of treating the CFTR-mediated disease cystic fibrosis comprising administering at least one of the novel compounds disclosed herein and / or at least one pharmaceutically acceptable salt thereof, <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-1-<com:Math><semantics>(2,2)<annotation encoding="application / x-tex">(2,2)< / annotation>< / semantics>< / com:Math>- difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound II), and N- [2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3- carboxamide (Compound III), optionally as part of at least one pharmaceutical composition comprising at least one additional component, to a patient in need thereof.
[0012] Also disclosed herein is Compound 1: [Image disponible dans le document PDF, Image available in the PDF document]
[0013] N-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3-trifluoro-2,2-dimethyl- propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide.
[0014] Also disclosed herein are pharmaceutical compositions of Compound 1, and forms thereof, which may include at least one additional active pharmaceutical ingredient and at least one carrier, and methods of treating the CFTR-mediated disease cystic fibrosis, comprising administering Compound 1 to a subject in need thereof. A process of making Compound 1 is also disclosed.
[0015] Brief Description of the Drawings
[0016] FIG. 1 shows the structures of non-limiting examples of novel compounds disclosed herein.
[0017] FIG. 2 is an XRPD of Form A of Compound 1.
[0018] FIG. 3 is an experimental XRPD of Form A of Compound 1 (top) compared to a calculated XRD (bottom), which is calculated from the single crystal data.
[0019] FIG. 4 is an overlay of the experimental and calculated XRPD of Form A of Compound 1 from FIG. 3.
[0020] FIG. 5 is an XRPD of a spray dried dispersion (SDD) of 50 wt% Compound 1 with HPMCAS-HG.
[0021] FIG. 6 is a MDSC spectrum of a SDD of 50 wt% Compound 1 with HPMCAS-HG.
[0022] FIG. 7 is a representative list of CFTR mutations.
[0023] FIG. 8 is a solid state Carbon-13 NMR spectrum of Form A of Compound 1, with MAS spinning at 12.5 kHz, referenced against adamantane 29.5 ppm, at 275 K. The spectrum was taken on a Bruker 400MHz WB SSNMR; BH085908; asset V019431 (console), V015741 (magnet).
[0024] FIG. 9 is a solid state Fluorine-19 NMR spectrum of Form A of Compound 1, with MAS spinning at 12.5 kHz, referenced against adamantane 29.5 ppm, at 275 K. The spectrum was taken on a Bruker 400MHz WB SSNMR; BH085908; asset V019431 (console), V015741 (magnet).
[0025] FIG. 10 shows a ball and stick plot of crystalline Form A of Compound 1.
[0026] FIG. 11 shows a TGA plot of crystalline Form A of Compound 1.
[0027] FIG. 12 shows a a dynamic vapor sorption (DVS) plot of crystalline Form A of Compound 1.
[0030] FIG. 13 shows an X-ray powder diffractogram of crystalline Form M of Compound 1.
[0031] FIG. 14 shows an X-ray powder diffractogram of crystalline Form E of Compound 1.
[0032] FIG. 15 shows an X-ray powder diffractogram of crystalline Form X of a potassium salt of Compound 1.
[0033] FIG. 16 shows an X-ray powder diffractogram of crystalline Form Y of a sodium salt of Compound 1.
[0034] FIG. 17 shows an X-ray powder diffractogram of crystalline Form P2 of Compound 1. Definitions
[0037] As used herein, the term "alkyl" refers to a saturated, branched or unbranched aliphatic hydrocarbon containing carbon atoms (such as, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms). Alkyl groups may be substituted or unsubstituted.
[0038] The term "alkoxy" as used herein refers to an alkyl or cycloalkyl covalently bonded to an oxygen atom. Alkoxy groups may be substituted or unsubstituted.
[0039] As used herein, "cycloalkyl" refers to a cyclic, bicyclic, tricyclic, or polycyclic non-aromatic hydrocarbon groups having 3 to 12 carbons (such as, for example 3-10 carbons). "Cycloalkyl" groups encompass monocyclic, bicyclic, tricyclic, bridged, fused, and spiro rings, including mono spiro and dispiro rings. Non-limiting examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, norbornyl, and dispiro[2.0.2.1]heptane. Cycloalkyl groups may be substituted or unsubstituted.
[0040] "Substituted," whether preceded by the term "optionally" or not, indicates that at least one hydrogen of the "substituted" group is replaced by a substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent chosen from a specified group, the substituent may be either the same or different at each position.
[0041] As used herein, "deuterated derivative(s)" means the same chemical structure, but with one or more hydrogen atoms replaced by a deuterium atom.
[0042] As used herein, "CFTR" means cystic fibrosis transmembrane conductance regulator.
[0043] As used herein, "mutations" can refer to mutations in the CFTR gene or the CFTR protein. A "CFTR gene mutation" refers to a mutation in the CFTR gene, and a "CFTR protein mutation" refers to a mutation in the CFTR protein. A genetic defect or mutation, or a change in the nucleotides in a gene in general results in a mutation in the CFTR protein translated from that gene, or a frame shift(s).
[0044] The term "F508del" refers to a mutant CFTR protein which is lacking the amino acid phenylalanine at position 508.
[0045] As used herein, a patient who is "homozygous" for a particular gene mutation has the same mutation on each allele.
[0046] As used herein, a patient who is "heterozygous" for a particular gene mutation has this mutation on one allele, and a different mutation on the other allele.
[0047] As used herein, the term "modulator" refers to a compound that increases the activity of a biological compound such as a protein. For example, a CFTR modulator is a compound that increases the activity of CFTR. The increase in activity resulting from a CFTR modulator includes but is not limited to compounds that correct, potentiate, stabilize and / or amplify CFTR.
[0048] As used herein, the term "CFTR corrector" refers to a compound that facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface. Compounds of Formulae (I), (II), (III), (IV), (V), and (VI), and Compound II, and their pharmaceutically acceptable salts thereof disclosed herein are CFTR correctors.
[0049] As used herein, the term "CFTR potentiator" refers to a compound that increases the channel activity of CFTR protein located at the cell surface, resulting in enhanced ion transport. Compound III disclosed herein is a CFTR potentiator.
[0050] As used herein, the term "active pharmaceutical ingredient" ("API") refers to a biologically active compound.
[0051] As used herein, the term "pharmaceutically acceptable salt" refers to a salt form of a compound of this disclosure wherein the salt is nontoxic. Pharmaceutically acceptable salts of the compounds of this disclosure include those derived from suitable inorganic and organic acids and bases. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19.
[0052] As used herein, the term "amorphous" refers to a solid material having no long range order in the position of its molecules. Amorphous solids are generally supercooled liquids in which the molecules are arranged in a random manner so that there is no well-defined arrangement, e.g., molecular packing, and no long range order. Amorphous solids are generally isotropic, i.e. exhibit similar properties in all directions and do not have definite melting points. For example, an amorphous material is a solid material having no sharp characteristic crystalline peak(s) in its X-ray power diffraction (XRPD) pattern (i.e., is not crystalline as determined by XRPD). Instead, one or several broad peaks (e.g., halos) appear in its XRPD pattern. Broad peaks are characteristic of an amorphous solid. See, US 2004 / 0006237 for a comparison of XRPDs of an amorphous material and crystalline material.
[0053] As used herein, the term "substantially amorphous" refers to a solid material having little or no long range order in the position of its molecules. For example, substantially amorphous materials have less than 15% crystallinity (e.g., less than 10%) crystallinity or less than 5% crystallinity). It is also noted that the term 'substantially amorphous' includes the descriptor, 'amorphous', which refers to materials having no (0%) crystallinity.
[0054] As used herein, the term "dispersion" refers to a disperse system in which one substance, the dispersed phase, is distributed, in discrete units, throughout a second substance (the continuous phase or vehicle). The size of the dispersed phase can vary considerably (e.g. colloidal particles of nanometer dimension, to multiple microns in size). In general, the dispersed phases can be solids, liquids, or gases. In the case of a solid dispersion, the dispersed and continuous phases are both solids. In pharmaceutical applications, a solid dispersion can include a crystalline drug (dispersed phase) in an amorphous polymer (continuous phase); or alternatively, an amorphous drug (dispersed phase) in an amorphous polymer (continuous phase). In some embodiments, a solid dispersion includes the polymer constituting the dispersed phase, and the drug constitute the continuous phase. Or, a solid dispersion includes the drug constituting the dispersed phase, and the polymer constituting the continuous phase.
[0055] The terms "patient" and "subject" are used interchangeably and refer to an animal including humans.
[0056] The terms "effective dose" and "effective amount" are used interchangeably herein and refer to that amount of a compound that produces the desired effect for which it is administered (e.g., improvement in CF or a symptom of CF, or lessening the severity of CF or a symptom of CF). The exact amount of an effective dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).
[0057] As used herein, the terms "treatment," "treating," and the like generally mean the improvement of CF or its symptoms or lessening the severity of CF or its symptoms in a subject. "Treatment," as used herein, includes, but is not limited to, the following: increased growth of the subject, increased weight gain, reduction of mucus in the lungs, improved pancreatic and / or liver function, reduction of chest infections, and / or reductions in coughing or shortness of breath. Improvements in or lessening the severity of any of these symptoms can be readily assessed according to standard methods and techniques known in the art.
[0058] As used herein, the term "in combination with," when referring to two or more compounds, agents, or additional active pharmaceutical ingredients, means the administration of two or more compounds, agents, or active pharmaceutical ingredients to the patient prior to, concurrent with, or subsequent to each other.
[0059] The terms "about" and "approximately", when used in connection with doses, amounts, or weight percent of ingredients of a composition or a dosage form, include the value of a specified dose, amount, or weight percent or a range of the dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent.
[0060] Each of compounds of Formulae (I), (II), (III), (IV), (V), and (VI), and Compounds II, III, IV, and pharmaceutically acceptable salts thereof, and their deuterated derivatives described herein independently can be administered once daily, twice daily, or three times daily. In some embodiments, at least one compound chosen from Compounds of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof, and their deuterated derivatives is administered once daily. In some embodiments, at least one compound chosen from Compounds of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof, and their deuterated derivatives are administered twice daily. In some embodiments, at least one compound chosen from Compound II and pharmaceutically acceptable salts thereof is administered once daily. In some embodiments, at least one compound chosen from Compound II and pharmaceutically acceptable salts thereof is administered twice daily. In some embodiments, at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof is administered once daily. In some embodiments, at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof is administered twice daily. In some embodiments, at least one compound chosen from Compound IV and pharmaceutically acceptable salts thereof is administered once daily. In some embodiments, at least one compound chosen from Compound IV and pharmaceutically acceptable salts thereof is administered twice daily. In some embodiments, a deuterated derivative of Compound II, III, and / or IV or a pharmaceutically acceptable salt thereof is employed in any one of these embodiments.
[0061] In some embodiments, 10 mg to 1,500 mg of a compound disclosed herein, a pharmaceutically acceptable salt thereof, or a deuterated derivative of such compound or salt are administered daily.
[0062] One of ordinary skill in the art would recognize that, when an amount of "a compound or a pharmaceutically acceptable salt thereof" is disclosed, the amount of the pharmaceutically acceptable salt form of the compound is the amount equivalent to the concentration of the free base of the compound. It is noted that the disclosed amounts of the compounds or their pharmaceutically acceptable salts thereof herein are based upon their free base form. For example, "10 mg of at least one compound chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof" includes 10 mg of a compound of Formula (I) and a concentration of a pharmaceutically acceptable salt of compounds of Formula (I) equivalent to 10 mg of compounds of Formula (I).
[0063] As stated above, disclosed herein are compounds of Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] (I), pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing, wherein: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; - X is chosen from O, NH, and <com:Math><semantics>N(C1−C4 alkyl)<annotation encoding="application / x-tex">N(C_1-C_4 \text{ alkyl})< / annotation>< / semantics>< / com:Math> groups; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen, halogens, cyano, hydroxyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxyl groups, and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxyl, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxyl groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each <com:Math><semantics>𝑹4<annotation encoding="application / x-tex">\mathbf{R}^4< / annotation>< / semantics>< / com:Math> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from halogens, cyano, hydroxyl, hydroxymethyl, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxyl groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxyl, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8.
[0064] Also disclosed herein are compounds of Formula (II): [Image disponible dans le document PDF, Image available in the PDF document] (II), pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing, wherein: - <com:Math><semantics>X<annotation encoding="application / x-tex">X< / annotation>< / semantics>< / com:Math> is chosen from O, NH, and N(C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl) groups; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen, halogens, cyano, hydroxyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxyl groups, and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxyl, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxyl groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from halogens, cyano, hydroxyl, hydroxymethyl, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxyl groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8. Encompassed within the scope of Formulae (I) and (II) are compounds comprising an [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl), i.e., wherein X is chosen from NH and <com:Math><semantics>N(C1−C4<annotation encoding="application / x-tex">N(C_1-C_4< / annotation>< / semantics>< / com:Math> alkyl) groups and pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing. In some embodiments, a compound having any one of the structural formulae shown in FIG. 1 but one of the (S=O) group of the sulfonamide group in each formula is replaced with NH or NR', or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing is encompassed, either as an isomeric mixture or enantioenriched (e.g., >90% ee, >95% ee, or >98% ee) isomers.
[0065] Also disclosed herein are compounds of Formula (III): [Image disponible dans le document PDF, Image available in the PDF document] (III), pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing, wherein: [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geninal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; - <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8.
[0066] In some embodiments, in compounds of Formulae (I), (II), and (III), pharmaceutically acceptable salts thereof, and / or deuterated derivatives of any of the foregoing: - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; and - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups.
[0067] In some embodiments, in compounds of Formulae (I), (II), and (III), pharmaceutically acceptable salts thereof, and / or deuterated derivatives of any of the foregoing: [Image disponible dans le document PDF, Image available in the PDF document] - <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxyl, and C<com:Sub>3< / com:Sub>- <com:Math><semantics>C10<annotation encoding="application / x-tex">C_{10}< / annotation>< / semantics>< / com:Math> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens, and - each <com:Math><semantics>𝑹2<annotation encoding="application / x-tex">\mathbf{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1-C2<annotation encoding="application / x-tex">C_1\text{-}C_2< / annotation>< / semantics>< / com:Math> alkyl groups, OH, <com:Math><semantics>C1-C2<annotation encoding="application / x-tex">C_1\text{-}C_2< / annotation>< / semantics>< / com:Math> alkoxyl groups, and halogens; - <com:Math><semantics>𝑹4<annotation encoding="application / x-tex">\mathbf{R}^4< / annotation>< / semantics>< / com:Math> is H; and - q is 0, 1, 2, 3, or 4.
[0068] In some embodiments, in compounds of Formulae (I), (II), and (III), pharmaceutically acceptable salts thereof, and / or deuterated derivatives of any of the foregoing, r is 0.
[0069] Also disclosed herein are compounds of Formula (IV): [Image disponible dans le document PDF, Image available in the PDF document] (IV) [Image disponible dans le document PDF, Image available in the PDF document] (V), or [Image disponible dans le document PDF, Image available in the PDF document] (VI), pharmaceutically acceptable salts of any of the foregoing, and deuterated derivatives of any of the foregoing, wherein: [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, OH, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, and halogens; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; and - p is 0, 1, or 2.
[0070] In some embodiments, p is 0 or 1. In some embodiments, p is 0.
[0071] In some embodiments, in compounds of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof, each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from CH<com:Sub>3< / com:Sub>, OH, F, and OCH<com:Sub>3< / com:Sub>. In some embodiments, p is 0 or 1. In some embodiments, p is 0.
[0072] In some embodiments, in compounds of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof, p is 1; <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math> is methyl; and <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is methyl.
[0073] In some embodiments, in compounds of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof, <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group. In some embodiments, <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with a halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math> alkyl group. In some embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with one or more halogens. In some embodiments, <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with one or more <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math> alkyl groups. In some embodiments, <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with one or more halogens and one or more <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math> alkyl groups. In some embodiments, <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a CF<com:Sub>3< / com:Sub> group. In some embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from C<com:Sub>4< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens. In some embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from <com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>- C<com:Sub>2< / com:Sub> alkyl groups, and halogens. In some embodiments, C<com:Sub>5< / com:Sub> cycloalkyl groups are bicyclic.
[0074] In some embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from <com:Math><semantics>ℂ7<annotation encoding="application / x-tex">\mathbb{C}_7< / annotation>< / semantics>< / com:Math> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens. In some embodiments, C<com:Sub>7< / com:Sub> cycloalkyl groups are bicyclic. In some embodiments, C<com:Sub>7< / com:Sub> cycloalkyl groups are tricyclic.
[0075] Also disclosed herein are compounds having a formula chosen from any one of the formulae depicted in FIG. 1 and pharmaceutically acceptable salts thereof.
[0076] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0077] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0078] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0079] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0080] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0081] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0082] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0083] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0084] Also disclosed herein is a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , , or [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0085] Also disclosed herein is a compound having any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] , , or [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0086] Also disclosed herein is a compound having any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] , , , , [Image disponible dans le document PDF, Image available in the PDF document] , or , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing.
[0087] Suitable pharmaceutically acceptable salts are, for example, those disclosed in S. M. Berge, et al. J. Pharmaceutical Sciences, 1977, 66, 1-19. For example, Table 1 of that article provides the following pharmaceutically acceptable salts: Table 1: [Image disponible dans le document PDF, Image available in the PDF document]
[0088] Non-limiting examples of pharmaceutically acceptable salts derived from appropriate acids include: salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, or perchloric acid; salts formed with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid; and salts formed by using other methods used in the art, such as ion exchange. Non-limiting examples of pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p- toluenesulfonate, undecanoate, and valerate salts. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and <com:Math><semantics>N+(C1−4alkyl)4<annotation encoding="application / x-tex">N^+(C_{1-4}alkyl)_4< / annotation>< / semantics>< / com:Math> salts. This disclosure also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Suitable non-limiting examples of alkali and alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium. Further non-limiting examples of pharmaceutically acceptable salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Other suitable, non-limiting examples of pharmaceutically acceptable salts include besylate and glucosamine salts.
[0089] In some embodiments, at least one compound chosen from the novel compounds disclosed herein, pharmaceutically acceptable salts thereof, and deuterated derivatives of the foregoing is administered in combination with at least one compound chosen from Compound II, pharmaceutically acceptable salts thereof, and deuterated derivatives of the foregoing. In some embodiments, at least one compound chosen from the novel compounds disclosed herein, pharmaceutically acceptable salts thereof, and deuterated derivatives of the foregoing is administered in combination with at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof. In some embodiments, at least one compound chosen from the novel compounds disclosed herein, pharmaceutically acceptable salts thereof, and deuterated derivatives of the foregoing is administered in combination with at least one compound chosen from Compound IV and pharmaceutically acceptable salts thereof. In some embodiments, at least one compound chosen from the novel compounds disclosed herein, pharmaceutically acceptable salts, and deuterated derivatives of the foregoing thereof is administered in combination with Compounds II or a pharmaceutically acceptable salt or deuterated derivative thereof and at least one compound chosen from Compound III, pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing. In some embodiments, at least one compound chosen from the novel compounds disclosed herein, pharmaceutically acceptable salts, and deuterated derivatives of any of the foregoing thereof is administered in combination with at least one compound chosen from Compound III, pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing and at least one compound chosen from Compound IV, pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing.
[0090] In some embodiments, at least one novel compound (and / or at least one pharmaceutically acceptable salt thereof and / or at least one deuterated derivative of such compound or salt) can be administered in combination with at least one additional active pharmaceutical ingredient. In some embodiments, at least one additional active pharmaceutical ingredient is chosen from: (a) Compound II: [Image disponible dans le document PDF, Image available in the PDF document] and pharmaceutically acceptable salts thereof. A chemical name for Compound II is (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N- (1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5- yl)cyclopropanecarboxamide; (b) Compound III: [Image disponible dans le document PDF, Image available in the PDF document] and pharmaceutically acceptable salts thereof. A chemical name for Compound III is N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo- 1H-quinoline-3-carboxamide; and (c) Compound IV: [Image disponible dans le document PDF, Image available in the PDF document] and pharmaceutically acceptable salts
[0091] A chemical name for Compound IV is 3-(6-(1-(2,2- difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2- yl)benzoic acid. In some embodiments, Compound 1 and / or a pharmaceutically acceptable salt thereof can be administered in combination with Compound II and / or a pharmaceutically acceptable salt thereof. In some embodiments, Compound 1 and / or a pharmaceutically acceptable salt thereof can be administered in combination with Compound III and / or a pharmaceutically acceptable salt thereof. In some embodiments, Compound 1 and / or a pharmaceutically acceptable salt thereof can be administered in combination with Compound IV and / or a pharmaceutically acceptable salt thereof. In some embodiments Compound 1 and / or a pharmaceutically acceptable salt thereof can be administered in combination with Compounds II and / or a pharmaceutically acceptable salt thereof and Compound III and / or a pharmaceutically acceptable salt thereof. In some embodiments Compound 1 and / or a pharmaceutically acceptable salt thereof can be administered in combination with Compounds II and / or a pharmaceutically acceptable salt thereof and Compound IV and / or a pharmaceutically acceptable salt thereof.
[0092] In one aspect, the disclosure features a pharmaceutical composition comprising Compound 1 and / or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0093] In one aspect, the disclosure features a pharmaceutical composition comprising Compound 1 and / or a pharmaceutically acceptable salt thereof, Compound II and / or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0094] In one aspect, the disclosure features a pharmaceutical composition comprising Compound 1 and / or a pharmaceutically acceptable salt thereof, Compound III and / or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0095] In one aspect, the disclosure features a pharmaceutical composition comprising Compound 1 and / or a pharmaceutically acceptable salt thereof, Compound II and / or a pharmaceutically acceptable salt thereof, Compound III and / or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0096] Any of the novel compounds disclosed herein, such as for example, compounds of Formula (I), (II), (III), (IV), (V), or (VI), and their pharmaceutically acceptable salts thereof, and deuterated derivatives of such compounds and salts can be comprised in a single pharmaceutical composition or separate pharmaceutical compositions in combination with other additional active pharmaceutical ingredient(s) (e.g., Compound II, III, or IV, or its pharmaceutically acceptable salt thereof, or a deuterated derivative of such Compound or salt). Such pharmaceutical compositions can be administered once daily or multiple times daily, such as twice daily. In some embodiments, the disclosure features a pharmaceutical composition comprising at least one compound chosen from any of the compounds disclosed herein and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
[0097] In some embodiments, the disclosure features a pharmaceutical composition comprising at least one compound chosen from the novel compounds disclosed herein and pharmaceutically acceptable salts thereof, at least one compound chosen from Compound II and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
[0098] In some embodiments, the disclosure features a pharmaceutical composition comprising at least one compound chosen from the novel compounds disclosed herein and pharmaceutically acceptable salts thereof, at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
[0099] In some embodiments, the disclosure features a pharmaceutical composition comprising at least one compound chosen from the novel compounds disclosed herein and pharmaceutically acceptable salts thereof, at least one compound chosen from Compound II and pharmaceutically acceptable salts thereof, at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
[00100] In some embodiments, the disclosure features a pharmaceutical composition comprising at least one compound chosen from the novel compounds disclosed herein and pharmaceutically acceptable salts thereof, at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof, at least one compound chosen from Compound IV and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier.
[00101] In some embodiments, pharmaceutical compositions disclosed herein comprise at least one additional active pharmaceutical ingredient. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR modulator. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR corrector. In some embodiments, the at least one additional active pharmaceutical ingredient is a CFTR potentiator. In some embodiments, the pharmaceutical composition comprises (i) a compound of Formulae (I), (II), (III), (IV), (V), or (VI), or a pharmaceutically acceptable salt thereof, or a deuterated derivative of such compound or salt; and (ii) at least two additional active pharmaceutical ingredients, one of which is a CFTR corrector and one of which is a CFTR potentiator.
[00102] In some embodiments, at least one additional active pharmaceutical ingredient is selected from mucolytic agents, bronchodialators, antibiotics, anti-infective agents, and anti-inflammatory agents.
[00103] A pharmaceutical composition may further comprise at least one pharmaceutically acceptable carrier. In some embodiments, the at least one pharmaceutically acceptable carrier is chosen from pharmaceutically acceptable vehicles and pharmaceutically acceptable adjuvants. In some embodiments, the at least one pharmaceutically acceptable is chosen from pharmaceutically acceptable fillers, disintegrants, surfactants, binders, lubricants.
[00104] It will also be appreciated that a pharmaceutical composition of this disclosure, including a pharmaceutical composition comprising combinations described previously, can be employed in combination therapies; that is, the compositions can be administered concurrently with, prior to, or subsequent to, at least one additional active pharmaceutical ingredient or medical procedures.
[00105] Pharmaceutical compositions comprising these combinations are useful for treating cystic fibrosis.
[00106] As described above, pharmaceutical compositions disclosed herein may optionally further comprise at least one pharmaceutically acceptable carrier. The at least one pharmaceutically acceptable carrier may be chosen from adjuvants and vehicles. The at least one pharmaceutically acceptable carrier, as used herein, includes any and all solvents, diluents, other liquid vehicles, dispersion aids, suspension aids, surface active agents, isotonic agents, thickening agents, emulsifying agents, preservatives, solid binders, and lubricants, as suited to the particular dosage form desired. Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier is incompatible with the compounds of this disclosure, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this disclosure. Non-limiting examples of suitable pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates, glycine, sorbic acid, and potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts, and electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars (such as lactose, glucose and sucrose), starches (such as corn starch and potato starch), cellulose and its derivatives (such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate), powdered tragacanth, malt, gelatin, talc, excipients (such as cocoa butter and suppository waxes), oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil), glycols (such as propylene glycol and polyethylene glycol), esters (such as ethyl oleate and ethyl laurate), agar, buffering agents (such as magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffer solutions, non-toxic compatible lubricants (such as sodium lauryl sulfate and magnesium stearate), coloring agents, releasing agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservatives, and antioxidants.
[00107] In some embodiments, the methods of the disclosure employ administering to a patient in need thereof at least one compound chosen from any of the compounds disclosed herein and pharmaceutically acceptable salts thereof, and at least one compound chosen from Compound II, Compound III, Compound IV, and pharmaceutically acceptable salts of any of the foregoing.
[00108] Any suitable pharmaceutical compositions known in the art can be used for the novel compounds disclosed herein, Compound II, Compound III, Compound IV, and pharmaceutically acceptable salts thereof. Some exemplary pharmaceutical compositions for Compound 1 and its pharmaceutically acceptable salts are described in the Examples. Some exemplary pharmaceutical compositions for Compound II and its pharmaceutically acceptable salts can be found in WO 2011 / 119984 and WO 2014 / 015841. Some exemplary pharmaceutical compositions for Compound III and its pharmaceutically acceptable salts can be found in WO 2007 / 134279, WO 2010 / 019239, WO 2011 / 019413, WO 2012 / 027731, and WO 2013 / 130669. Some exemplary pharmaceutical compositions for Compound IV and its pharmaceutically acceptable salts can be found in WO 2010 / 037066, WO 2011 / 127241, WO 2013 / 112804, and WO 2014 / 071122.
[00109] In some embodiments, a pharmaceutical composition comprising at least one compound chosen from the novel compounds disclosed herein and pharmaceutically acceptable salts thereof is administered with a pharmaceutical composition comprising Compound II and Compound III. Pharmaceutical compositions comprising Compound II and Compound III are disclosed in PCT Publication No. WO 2015 / 160787. An exemplary embodiment is shown in the following Table 2:
[00110] Table 2. Exemplary Tablet Comprising 100 mg of Compound II and 150 mg of Compound III. [Image disponible dans le document PDF, Image available in the PDF document]
[00111] In some embodiments, a pharmaceutical composition comprising at least one compound chosen from the novel compounds disclosed herein and pharmaceutical salts thereof is administered with a pharmaceutical composition comprising Compound III. Pharmaceutical compositions comprising Compound III are disclosed in PCT Publication No. WO 2010 / 019239. An exemplary embodiment is shown in the following Table 3:
[00112] Table 3: Ingredients for Exemplary Tablet of Compound III. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]
[00113] Additional pharmaceutical compositions comprising Compound III are disclosed in PCT Publication No. WO 2013 / 130669. Exemplary mini-tablets (~2 mm diameter, ~2 mm thickness, each mini-tablet weighing about 6.9 mg) was formulated to have approximately 50 mg of Compound III per 26 mini-tablets and approximately 75 mg of Compound III per 39 mini-tablets using the amounts of ingredients recited in Table 4, below.
[00114] Table 4: Ingredients for mini-tablets for 50 mg and 75 mg potency [Image disponible dans le document PDF, Image available in the PDF document]
[00115] In some embodiments, the pharmaceutical compositions are a tablet. In some embodiments, the tablets are suitable for oral administration.
[00116] The compounds, pharmaceutically acceptable salts thereof, and deuterated analogs of any of the foregoing, and pharmaceutical compositions, of this disclosure, either in monotherapies or in combo-therapies are useful for treating cystic fibrosis.
[00117] In some embodiments, disclosed herein are methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of a compound, pharmaceutically acceptable salt thereof, or a deuterated analog of any of the foregoing; or a pharmaceutical composition, of this disclosure to a patient, such as a human, wherein said patient has cystic fibrosis. In some embodiments, the patient has F508del / minimal function (MF) genotypes, F508del / F508del genotypes, F508del / gating genotypes, or F508del / residual function (RF) genotypes.
[00118] Patients with an F508del / minimal function genotype are defined as patients that are heterozygous F508del-CFTR with a second CFTR allele containing a mutation that is predicted to result in a CFTR protein with minimal function and that is not expected to respond to Compound II, Compound III, or the combination of Compound II and Compound III. These CFTR mutations were defined using 3 major sources: biological plausibility for the mutation to respond (i.e., mutation class) evidence of clinical severity on a population basis (per CFTR2 patient registry; accessed on 15 February 2016) o average sweat chloride >86 mmol / L, and 0 prevalence of pancreatic insufficiency (PI) >50% in vitro testing 0 mutations resulting in baseline chloride transport <10% of wild-type CFTR were considered minimal function 0 mutations resulting in chloride transport <10% of wild-type CFTR following the addition of Compound II and / or Compound III were considered nonresponsive.
[00119] Patients with an F508del / residual function genotype are defined as patients that are heterozygous F508del-CFTR with a second CFTR allele that contains a mutation that results in reduced protein quantity or function at the cell surface which can produce partial CFTR activity. CFTR gene mutations known to result in a residual function phenotype include in some embodiments, a CFTR residual function mutation selected from <com:Math><semantics>2789+5G→A<annotation encoding="application / x-tex">2789+5G \rightarrow A< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3849+10kbC→T<annotation encoding="application / x-tex">3849+10kbC \rightarrow T< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3272−26A→G<annotation encoding="application / x-tex">3272-26A \rightarrow G< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>711+3A→G<annotation encoding="application / x-tex">711+3A \rightarrow G< / annotation>< / semantics>< / com:Math>, E56K, P67L, R74W, D110E, D110H, R117C, L206W, R347H, R352Q, A455E, D579G, E831X, S945L, S977F, F1052V, R1070W, F1074L, D1152H, D1270N, E193K, and K1060T. In some embodiments, the CFTR residual function mutation is selected from R117H, S1235R, I1027T, R668C, G576A, M470V, L997F, R75Q, R1070Q, R31C, D614G, G1069R, R1162L, E56K, A1067T, E193K, or K1060T. In some embodiments, the CFTR residual function mutation is selected from R117H, S1235R, I1027T, R668C, G576A, M470V, L997F, R75Q, R1070Q, R31C, D614G, G1069R, R1162L, E56K, or A1067T.
[00120] Patients with an F508del / gating mutation genotype are defined as patients that are heterozygous F508del-CFTR with a second CFTR allele that contains a mutation associated with a gating defect and clinically demonstrated to be responsive to Compound III. Examples of such mutations include: G178R, S549N, S549R, G551D, G551S, G1244E, S1251N, S1255P, and G1349D.
[00121] In some embodiments, the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein are each independently produces an increase in chloride transport above the baseline chloride transport of the patient.
[00122] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient is heterozygous for F508del, and the other CFTR mutation is any CF-causing mutation. In some embodiments, the paitent is heterozygous for F508del, and the other CFTR mutation is any CF-causing mutation, and is expected to be and / or is responsive to any of the novel compounds disclosed herein, such as Compound 1, Compound II, Compound III and / or Compound IV genotypes based on in vitro and / or clinical data. In some embodiments, the paitent is heterozygous for F508del, and the other CFTR mutation is any CF-causing mutation, and is expected to be and / or is responsive to any combinations of (i) the novel compounds disclosed herein, such as Compound 1, and (ii) Compound II, and / or Compound III and / or Compound IV genotypes based on in vitro and / or clinical data. In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation selected from any of the mutations listed in Table 5. Table 5. CFTR Mutations [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] JUJJUCIU [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] W1089X [Image disponible dans le document PDF, Image available in the PDF document] W1098C W1098R W1098X W1204X W1282R W1282X W361R W401X W496X W57G W57R W57X W846X Y1014C Y1032C а Also known as <com:Math><semantics>2183delAA→G<annotation encoding="application / x-tex">2183 delAA \rightarrow G< / annotation>< / semantics>< / com:Math>.
[00123] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, $549R, $1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA- >G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T- >C, 621+3A->G, 1949del84, 3141del9, 3195del6, 3199del6, 3905InsT, 4209TGTT->A, A1006E, A120T, A234D, A349V, A613T, C524R, D192G, D443Y, D513G, D836Y, D924N, D979V, E116K, E403D, E474K, E588V, E60K, E822K, F1016S, F1099L, F191V, F311del, F311L, F508C, F575Y, G1061R, G1249R, G126D, G149R, G194R, G194V, G27R, G314E, G458V, G463V, G480C, G622D, G628R, G628R(G->A), G91R, G970D, H1054D, H1085P, H1085R, H1375P, H139R, H199R, H609R, H939R, 11005R, 11234V, 11269N, 11366N, 1175V, 1502T, 1506S, 1506T, 1601F, 1618T, 1807M, 1980K, L102R, L1324P, L1335P, L138ins, L1480P, L15P, L165S, L320V, L346P, L453S, L571S, L967S, M1101R, M152V, M1T, M1V, M265R, M952I, M952T, P574H, P5L, P750L, P99L, Q1100P, Q1291H, Q1291R, Q237E, Q237H, Q452P, Q98R, R1066C, R1066H, R117G, R117L, R117P, R1283M, R1283S, R170H, R258G, R31L, R334L, R334Q, R347L, R352W, R516G, R553Q, R751L, R792G, R933G, S1118F, S1159F, S1159P, S13F, S549R(A->C), S549R(T->G), S589N, S737F, S912L, T1036N, T1053I, T1246I, T604I, V1153E, V1240G, V1293G, V201M, V232D, V456A, V456F, V562I, W1098C, W1098R, W1282R, W361R, W57G, W57R, Y1014C, Y1032C, Y109N, Y161D, Y161S, Y563D, Y563N, Y569C, and Y913C.
[00124] In some embodiments, the patient has at least one combination mutation chosen from: G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA- >G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T- >C, and 621+3A->G.
[00125] In some embodiments, the patient has at least one combination mutation chosen from: 1949del84, 3141del9, 3195del6, 3199del6, 3905InsT, 4209TGTT->A, A1006E, A120T, A234D, A349V, A613T, C524R, D192G, D443Y, D513G, D836Y, D924N, D979V, E116K, E403D, E474K, E588V, E60K, E822K, F1016S, F1099L, F191V, F311del, F311L, F508C, F575Y, G1061R, G1249R, G126D, G149R, G194R, G194V, G27R, G314E, G458V, G463V, G480C, G622D, G628R, G628R(G->A), G91R, G970D, H1054D, H1085P, H1085R, H1375P, H139R, H199R, H609R, H939R, I1005R, I1234V, I1269N, I1366N, I175V, I502T, I506S, I506T, I601F, I618T, I807M, I980K, L102R, L1324P, L1335P, L138ins, L1480P, L15P, L165S, L320V, L346P, L453S, L571S, L967S, M1101R, M152V, M1T, M1V, M265R, M952I, M952T, P574H, P5L, P750L, P99L, Q1100P, Q1291H, Q1291R, Q237E, Q237H, Q452P, Q98R, R1066C, R1066H, R117G, R117L, R117P, R1283M, R1283S, R170H, R258G, R31L, R334L, R334Q, R347L, R352W, R516G, R553Q, R751L, R792G, R933G, S1118F, S1159F, S1159P, S13F, S549R(A->C), S549R(T->G), S589N, S737F, S912L, T1036N, T1053I, T1246I, T604I, V1153E, V1240G, V1293G, V201M, V232D, V456A, V456F, V562I, W1098C, W1098R, W1282R, W361R, W57G, W57R, Y1014C, Y1032C, Y109N, Y161D, Y161S, Y563D, Y563N, Y569C, and Y913C.
[00126] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation G551D. In some embodiments, the patient is homozygous for the G551D mutation. In some embodiments, the patient is heterozygous for the G551D mutation. In some embodiments, the patient is heterozygous for the G551D mutation, having the G551D mutation on one allele and any other CF-causing mutation on the other allele. In some embodiments, the patient is heterozygous for the G551D genetic mutation on one allele and the other CF-causing mutation on the other allele is any one of F508del, G542X, N1303K, W1282X, R117H, R553X, 1717-1G->A, 621+1G->T, 2789+5G->A, <com:Math><semantics>3849+10<annotation encoding="application / x-tex">3849+10< / annotation>< / semantics>< / com:Math>kbC->T, R1162X, G85E, 3120+1G->A, <com:Math><semantics>Δ<annotation encoding="application / x-tex">\Delta< / annotation>< / semantics>< / com:Math>I507, 1898+1G->A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711+1G->T. In some embodiments, the patient is heterozygous for the G551D mutation, and the other CFTR mutation is F508del. In some embodiments, the patient is heterozygous for the G551D mutation, and the other CFTR mutation is R117H.
[00127] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation F508del. In some embodiments, the patient is homozygous for the F508del mutation. In some embodiments, the patient is heterozygous for the F508del mutation wherein the patient has the F508del mutation on one allele and any CF-causing mutation on the other allele. In some embodiments, the patient is heterozygous for F508del, and the other CFTR mutation is any CF-causing mutation, including, but not limited to G551D, G542X, N1303K, W1282X, R117H, R553X, 1717-1G->A, 621+1G- <com:Math><semantics>T<annotation encoding="application / x-tex">T< / annotation>< / semantics>< / com:Math>, 2789+5G-<com:Math><semantics>A<annotation encoding="application / x-tex">A< / annotation>< / semantics>< / com:Math>, 3849+10kbC-<com:Math><semantics>T<annotation encoding="application / x-tex">T< / annotation>< / semantics>< / com:Math>, R1162X, G85E, 3120+1G-<com:Math><semantics>A<annotation encoding="application / x-tex">A< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>Δ<annotation encoding="application / x-tex">\Delta< / annotation>< / semantics>< / com:Math>I507, 1898+1G- >A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711+1G->T. In some embodiments, the patient is heterozygous for F508del, and the other CFTR mutation is G551D. In some embodiments, the patient is heterozygous for F508del, and the other CFTR mutation is R117H.
[00128] In some embodiments, the patient has at least one combination mutation chosen from: (i) D443Y;G576A;R668C, (iii) G576A; R668C, (iv) G970R; M470V, (v) R74W;D1270N, (vi) R74W; V201M, and (vii) R74W;V201M;D1270N.
[00129] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R. In some embodiments, the patient possesses a CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N. In some embodiments, the patient possesses a CFTR mutation selected from E193K, F1052V and G1069R. In some embodiments, the method produces an increase in chloride transport relative to baseline chloride transport of the patient of the patient.
[00130] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N and D1152H.
[00131] In some embodiments, the patient possesses a CFTR mutation selected from 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A- >G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A- >G. In some embodiments, the patient possesses a CFTR mutation selected from 1717- 1G->A, 1811+1.6kbA->G, 2789+5G->A, 3272-26A->G and 3849+10kbC->T. In some embodiments, the patient possesses a CFTR mutation selected from 2789+5G->A and 3272-26A->G.
[00132] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, $549R, $1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA- >G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A->G, and CFTR mutations selected from F508del, R117H, and G551D.
[00133] In some embodiments, in the methods of treating, lessening the severity of, or symptomatically treating cystic fibrosis disclosed herein, the patient possesses a CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, $549R, $1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA- >G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T- >C, 621+3A->G, and a CFTR mutation selected from F508del, R117H, and G551D; and a CFTR mutations selected from F508del, R117H, and G551D.
[00134] In some embodiments, the patient possesses a CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R, and a CFTR mutation selected from F508del, R117H, and G551D. In some embodiments, the patient possesses a CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N, and a CFTR mutation selected from F508del, R117H, and G551D. In some embodiments, the patient possesses a CFTR mutation selected from E193K, F1052V and G1069R, and a CFTR mutation selected from F508del, R117H, and G551D.
[00135] In some embodiments, the patient possesses a CFTR mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N and D1152H, and a CFTR mutation selected from F508del, R117H, and G551D.
[00136] In some embodiments, the patient possesses a CFTR mutation selected from 1717-1G->A, 621+1G->T, 3120+1G->A, 1898+1G->A, 711+1G->T, 2622+1G->A, 405+1G->A, 406-1G->A, 4005+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-1G->A, 4374+1G->T, 3850-1G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A- >G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G / A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A- >G, and a CFTR mutation selected from F508del, R117H, and G551D. In some embodiments, the patient possesses a CFTR mutation selected from 1717-1G->A, 1811+1.6kbA->G, 2789+5G->A, 3272-26A->G and 3849+10kbC->T, and a CFTR mutation selected from F508del, R117H, and G551D. In some embodiments, the patient possesses a CFTR mutation selected from 2789+5G->A and 3272-26A->G, and a CFTR mutation selected from F508del, R117H.
[00137] In some embodiments, the patient is heterozygous having a CF-causing mutation on one allele and a CF-causing mutation on the other allele. In some embodiments, the patient is heterozygous for F508del, and the other CFTR-causing mutation is any CF-causing mutation, including, but not limited to F508del on one CFTR allele and a CFTR mutation on the second CFTR allele that is associated with minimal CFTR function, residual CFTR function, or a defect in CFTR channel gating activity. In some embodiments, the CF-causing mutation is selected from Table 5. In some embodiments, the CF-causing mutation is selected from Table 6. In some embodiments, the CF-causing mutation is selected from Table 7.
[00138] In some embodiments, the patient is heterozygous having a CFTR mutation on one CFTR allele selected from the mutations listed in the table from FIG. 7 and a CFTR mutation on the other CFTR allele is selected from the CFTR mutations listed in Table 6: Table 6: CFTR Mutations [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Table 7: CFTR Mutations [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Note: %PI: percentage of F508del-CFTR heterozygous patients in the CFTR2 patient registry who are pancreatic insufficient; SwCl<com:Sup>-< / com:Sup>: mean sweat chloride of F508del-CFTR heterozygous patients in the CFTR2 patient registry Also known as <com:Math><semantics>2183delAA→G<annotation encoding="application / x-tex">2183 delAA \rightarrow G< / annotation>< / semantics>< / com:Math>. Unpublished data.
[00139] Table 7 above includes certain exemplary CFTR minimal function mutations, which are detectable by an FDA-cleared genotyping assay, but does not include an exhaustive list.
[00140] In some embodiments, the patient is: with <com:Math><semantics>F508del / MF<annotation encoding="application / x-tex">F508del / MF< / annotation>< / semantics>< / com:Math> (F / MF) genotypes (heterozygous for F508del and an MF mutation not expected to respond to CFTR modulators, such as Compound III); with F508del / F508del (F / F) genotype (homozygous for F508del); and / or with <com:Math><semantics>F508del<annotation encoding="application / x-tex">F508del< / annotation>< / semantics>< / com:Math> / gating (F / G) genotypes (heterozygous for F508del and a gating mutation known to be CFTR modulator-responsive (e.g., Compound III-responsive). In some embodiments, the patient with <com:Math><semantics>F508del / MF<annotation encoding="application / x-tex">F508del / MF< / annotation>< / semantics>< / com:Math> (F / MF) genotypes has a MF mutation that is not expected to respond to Compound II, Compound III, and both of Compound II and Compound III. In some embodiments, the patient with <com:Math><semantics>F508del / MF<annotation encoding="application / x-tex">F508del / MF< / annotation>< / semantics>< / com:Math> (F / MF) genotypes has any one of the MF mutations in Table 7.
[00141] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any CF-causing mutation, including truncation mutations, splice mutations, small (<com:Math><semantics>≤3<annotation encoding="application / x-tex">\leq 3< / annotation>< / semantics>< / com:Math> nucleotide) insertion or deletion (ins / del) frameshift mutations; non-small (>3 nucleotide) insertion or deletion (ins / del) frameshift mutations; and Class II, III, IV mutations not responsive to Compound III alone or in combination with Compound II or Compound IV.
[00142] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is a truncation mutation. In some specific embodiments, the truncation mutation is a truncation mutation listed in Table 7.
[00143] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is a splice mutation. In some specific embodiments, the splice mutation is a splice mutation listed in Table 7.
[00144] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is a small (<com:Math><semantics>≤3<annotation encoding="application / x-tex">\leq 3< / annotation>< / semantics>< / com:Math> nucleotide) insertion or deletion (ins / del) frameshift mutation. In some specific embodiments, the small (<com:Math><semantics>≤3<annotation encoding="application / x-tex">\leq 3< / annotation>< / semantics>< / com:Math> nucleotide) insertion or deletion (ins / del) frameshift mutation is a small (<com:Math><semantics>≤3<annotation encoding="application / x-tex">\leq 3< / annotation>< / semantics>< / com:Math> nucleotide) insertion or deletion (ins / del) frameshift mutation listed in Table 7.
[00145] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any CF-causing mutation expected to be and / or is responsive to, based on in vitro and / or clinical data, any combination of (i) a novel compound chosen from those disclosed herein (e.g., compounds of Formula (I), (II), (III), (IV), (V), or (VI), and pharmaceutically acceptable salts thereof, and their deuterated derivatives), and (ii) Compound II, and / or Compound III, and / or Compound IV.
[00146] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any CF-causing mutation expected to be and / or is responsive, based on in vitro and / or clinical data, to the triple combination of a novel compound chosen from those disclosed herein (e.g., compounds of Formula (I), (II), (III), (IV), (V), or (VI), and pharmaceutically acceptable salts thereof, and their deuterated derivatives), and Compound II, and Compound III.
[00147] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is a non-small (>3 nucleotide) insertion or deletion (ins / del) frameshift mutation. In some specific embodiments, the non-small (>3 nucleotide) insertion or deletion (ins / del) frameshift mutation is a non-small (>3 nucleotide) insertion or deletion (ins / del) frameshift mutation listed in Table 6.
[00148] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is a Class II, III, IV mutations not responsive to Compound III alone or in combination with Compound II or Compound IV. In some embodiments, the Class II, III, IV mutations not responsive to Compound III alone or in combination with Compound II or Compound IV is a Class II, III, IV mutations not responsive to Compound III alone or in combination with Compound II or Compound IV listed in Table 7.
[00149] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any mutation listed in Table 7.
[00150] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any mutation, but other than F508del, listed in Table 5, 6, 7, and FIG. 7.
[00151] In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any mutation listed in Table 5. In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any mutation listed in Table 6. In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any mutation listed in Table 7. In some embodiments, the patient is heterozygous for F508del, and the other CFTR genetic mutation is any mutation listed in FIG. 7.
[00152] In some embodiments, the patient is homozygous for F508del.
[00153] In some embodiments, the patient is heterozygous having one CF-causing mutation on one CFTR allele selected from the mutations listed in the table from FIG. 7 and another CF-causing mutation on the other CFTR allele is selected from the CFTR mutations listed in Table 7.
[00154] In some embodiments, the composition disclosed herein is useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients who exhibit residual CFTR activity in the apical membrane of respiratory and non- respiratory epithelia. The presence of residual CFTR activity at the epithelial surface can be readily detected using methods known in the art, e.g., standard electrophysiological, biochemical, or histochemical techniques. Such methods identify CFTR activity using in vivo or ex vivo electrophysiological techniques, measurement of sweat or salivary Cl<com:Sup>-< / com:Sup> concentrations, or ex vivo biochemical or histochemical techniques to monitor cell surface density. Using such methods, residual CFTR activity can be readily detected for patients that are heterozygous or homozygous for a variety of different mutations, including patients heterozygous for the most common mutation, F508del, as well as other mutations such as the G551D mutation, or the R117H mutation. In some embodiments, compositions disclosed herein are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients who exhibit little to no residual CFTR activity. In some embodiments, compositions disclosed herein are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients who exhibit little to no residual CFTR activity in the apical membrane of respiratory epithelia.
[00155] In some embodiments, the compositions disclosed herein are useful for treating or lessening the severity of cystic fibrosis in patients who exhibit residual CFTR activity using pharmacological methods. Such methods increase the amount of CFTR present at the cell surface, thereby inducing a hitherto absent CFTR activity in a patient or augmenting the existing level of residual CFTR activity in a patient.
[00156] In some embodiments, the compositions disclosed herein are useful for treating or lessening the severity of cystic fibrosis in patients with certain genotypes exhibiting residual CFTR activity.
[00157] In some embodiments, compositions disclosed herein are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients within certain clinical phenotypes, e.g., a mild to moderate clinical phenotype that typically correlates with the amount of residual CFTR activity in the apical membrane of epithelia. Such phenotypes include patients exhibiting pancreatic sufficiency.
[00158] In some embodiments, the compositions disclosed herein are useful for treating, lessening the severity of, or symptomatically treating patients diagnosed with pancreatic sufficiency, idiopathic pancreatitis and congenital bilateral absence of the vas deferens, or mild lung disease wherein the patient exhibits residual CFTR activity.
[00159] In some embodiments, this disclosure relates to a method of augmenting or inducing anion channel activity in vitro or in vivo, comprising contacting the channel with a composition disclosed herein. In some embodiments, the anion channel is a chloride channel or a bicarbonate channel. In some embodiments, the anion channel is a chloride channel.
[00160] The exact amount of a pharmaceutical composition required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular agent, its mode of administration, and the like. The compounds of this disclosure may be formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of this disclosure will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term "patient", as used herein, means an animal, such as a mammal, and even further such as a human.
[00161] In some embodiments, the disclosure also is directed to methods of treatment using isotope-labelled compounds of the afore-mentioned compounds, which have the same structures as disclosed herein except that one or more atoms therein have been replaced by an atom or atoms having an atomic mass or mass number which differs from the atomic mass or mass number of the atom which usually occurs naturally (isotope labelled). Examples of isotopes which are commercially available and suitable for the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, for example <com:Sup>2< / com:Sup>H, <com:Sup>3< / com:Sup>H, <com:Sup>13< / com:Sup>C, <com:Sup>14< / com:Sup>C, <com:Sup>15< / com:Sup>N, <com:Sup>18< / com:Sup>O, <com:Sup>17< / com:Sup>O, <com:Sup>31< / com:Sup>P, <com:Sup>32< / com:Sup>P, <com:Sup>35< / com:Sup>S, <com:Sup>18< / com:Sup>F and <com:Sup>36< / com:Sup>Cl, respectively.
[00162] The isotope-labelled compounds and salts can be used in a number of beneficial ways. They can be suitable for medicaments and / or various types of assays, such as substrate tissue distribution assays. For example, tritium (<com:Sup>3< / com:Sup>H)- and / or carbon-14 (<com:Sup>14< / com:Sup>C)-labelled compounds are particularly useful for various types of assays, such as substrate tissue distribution assays, due to relatively simple preparation and excellent detectability. For example, deuterium (<com:Sup>2< / com:Sup>H)-labelled ones are therapeutically useful with potential therapeutic advantages over the non-<com:Sup>2< / com:Sup>H-labelled compounds. In general, deuterium (<com:Sup>2< / com:Sup>H)-labelled compounds and salts can have higher metabolic stability as compared to those that are not isotope-labelled owing to the kinetic isotope effect described below. Higher metabolic stability translates directly into an increased in vivo half-life or lower dosages, which could be desired. The isotope-labelled compounds and salts can usually be prepared by carrying out the procedures disclosed in the synthesis schemes and the related description, in the example part and in the preparation part in the present text, replacing a non-isotope-labelled reactant by a readily available isotope-labelled reactant.
[00163] In some embodiments, the isotope-labelled compounds and salts are deuterium (<com:Sup>2< / com:Sup>H)-labelled ones. In some specific embodiments, the isotope-labelled compounds and salts are deuterium (<com:Sup>2< / com:Sup>H)-labelled, wherein one or more hydrogen atoms therein have been replaced by deuterium. In chemical structures, deuterium is represented as "2H" or "D."
[00164] The deuterium (<com:Sup>2< / com:Sup>H)-labelled compounds and salts can manipulate the oxidative metabolism of the compound by way of the primary kinetic isotope effect. The primary kinetic isotope effect is a change of the rate for a chemical reaction that results from exchange of isotopic nuclei, which in turn is caused by the change in ground state energies necessary for covalent bond formation after this isotopic exchange. Exchange of a heavier isotope usually results in a lowering of the ground state energy for a chemical bond and thus causes a reduction in the rate-limiting bond breakage. If the bond breakage occurs in or in the vicinity of a saddle-point region along the coordinate of a multi-product reaction, the product distribution ratios can be altered substantially. For explanation: if deuterium is bonded to a carbon atom at a non- exchangeable position, rate differences of <com:Math><semantics>kM / kD=2−7<annotation encoding="application / x-tex">k_{M} / k_D = 2-7< / annotation>< / semantics>< / com:Math> are typical. For a further discussion, see S. L. Harbeson and R. D. Tung, Deuterium In Drug Discovery and Development, Ann. Rep. Med. Chem. 2011, 46, 403-417; and T.G. Gant "Using deuterium in drug discovery: leaving the label in the drug" J. Med. Chem. 2014, 57, 3595-3611
[00165] The concentration of the isotope(s) (e.g., deuterium) incorporated into the isotope-labelled compounds and salt of the disclosure may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. In some embodiments, if a substituent in a compound of the disclosure is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5%) deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
[00166] When discovering and developing therapeutic agents, the person skilled in the art attempts to optimize pharmacokinetic parameters while retaining desirable in vitro properties. It may be reasonable to assume that many compounds with poor pharmacokinetic profiles are susceptible to oxidative metabolism.
[00167] One of ordinary skill in the art would understand that deuteration of one or more metabolically labile positions on a compound or active metabolite may lead to improvement of one or more superior DMPK properties while maintaining biological activity as compared to the corresponding hydrogen analogs. The superior DMPK property or properties may have an impact on the exposure, half-life, clearance, metabolism, and / or even food requirements for optimal absorption of the drug product. Deuteration may also change the metabolism at other non-deuterated positions of the deuterated compound.
[00168] In some embodiments, the disclosure includes deuterated derivatives of the novel compounds disclosed herein and of their pharmaceutically acceptable salts. Non- limiting examples of deuterated compounds are disclosed in FIG. 1.
[00169] In some embodiments, Compound III' as used herein includes the deuterated compound disclosed in U.S. Patent No. 8,865,902, and CTP-656.
[00170] In some embodiments, Compound III' is: [Image disponible dans le document PDF, Image available in the PDF document]
[00171] Exemplary embodiments of the disclosure include: The novel compounds disclosed herein (e.g., compounds of Formulae <com:Math><semantics>(I)−(VI)<annotation encoding="application / x-tex">(I) - (VI)< / annotation>< / semantics>< / com:Math>, pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing, including the compounds in FIG. 1 and those specifically depicted herein) can be prepared by suitable methods known in the art. For example, they can be prepared in accordance with procedures described in WO 2016 / 057572 and by the exemplary syntheses described below in the Examples. For example, deuterated derivatives of the novel compounds of Formulae (I) – (VI) and pharmaceutically acceptable salts thereof can be prepared in a similar manner as those for compounds of Formulae <com:Math><semantics>(I)−(VI)<annotation encoding="application / x-tex">(I) - (VI)< / annotation>< / semantics>< / com:Math> and pharmaceutically acceptable salts thereof by employing intermediates and / or reagents where one or more hydrogen atoms are replaced with deuterium. For example, see T.G. Gant "Using deuterium in drug discovery: leaving the label in the drug," J. Med. Chem. 2014, 57, 3595-3611.
[00172] In some embodiments, compounds of Formulae (X), (III), (IV), (V), and (VI) and pharmaceutically acceptable salts thereof, and deuterated derivatives of any of the foregoing are prepared as depicted in Schemes 1-2, wherein the variables therein are each and independently are as those for Formula (I), (II), (III), (IV), (V), or (VI) above, and wherein each R<com:Sup>a< / com:Sup> is independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl groups; and each X<com:Sup>a< / com:Sup> is independently chosen from F or Cl. Suitable condition(s) known in the art can be employed for each step depicted in the schemes. In some embodiments, each X<com:Sup>a< / com:Sup> for Formulae (B), (C), (D), (F), (B-1), (C-1), (D-1), and (F-1) in Schemes 2-4 is independently Cl. In some embodiments, each X<com:Sup>a< / com:Sup> for Formulae (D), (L), (O), and (P) in Scheme 6 is independently F. In some embodiments, r in Formulae (X), (B), (C), (D), and (F) is independently 0.
[00173] In some embodiments, as shown in Scheme 1, the methods comprise reacting a compound of Formula (F) or a salt thereof with a compound of Formula (G) or a salt thereof to generate a compound of Formula (X), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. Scheme 1 [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(Λ)<annotation encoding="application / x-tex">(\Lambda)< / annotation>< / semantics>< / com:Math>
[00174] In some embodiments, in said Formulae (F), (G) and (X): - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; [Image disponible dans le document PDF, Image available in the PDF document] - each <Formule mathématique disponible dans le document PDF, Math available in the PDF document>${\bf R}^2$ is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each <com:Math><semantics>𝑹4<annotation encoding="application / x-tex">\mathbf{R}^4< / annotation>< / semantics>< / com:Math> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - X<com:Sup>a< / com:Sup> is F or Cl; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8.
[00175] In some embodiments, r in Formula (X) is 0.
[00176] Any suitable conditions, such as those for a nucleophilic reaction of amine, known in the art can be used. In some embodiments, the reaction depicted in Scheme 1 is performed in the presence of a base, such as a metal carbonate (e.g., Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> or <com:Math><semantics>K2CO3<annotation encoding="application / x-tex">K_2CO_3< / annotation>< / semantics>< / com:Math>).
[00177] In some embodiments, compounds of Formula (X), pharmaceutically acceptable salts thereof, or deuterated derivatives of any of the foregoing, wherein Y<com:Sup>2< / com:Sup> is N and Y<com:Sup>1< / com:Sup> is CH in each of Formulae (F), (G) and (X), are prepared by the methods in Scheme 1.In some embodiments, a salt of a compound of Formula (G) is employed. In some embodiments, an HCl salt of a compound of Formula (G) is employed.
[00178] A compound of Formula (F) or a salt thereof and a compound of Formula (G) or a salt thereof can be prepared by any suitable method known in the art, for example, those in WO 2016 / 57572 and those in the exemplary syntheses described below in the Examples.
[00179] In some embodiments, as shown in Scheme 2, a compound of Formula (F), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing is prepared by a method that comprises reacting a compound of Formula (D) or a salt thereof with a compound of Formula (E) or a salt thereof. In some embodiments, compounds of Formula (D), salts thereof, or deuterated derivatives of any of the foregoing are prepared by a method that comprises reacting a compound of Formula (A) or a salt thereof with a compound of Formula (B) or a salt thereof to generate a compound of Formula (C) or a salt thereof; and hydrolyzing the -C(O)OR<com:Sup>a< / com:Sup> of compound of Formula (C) to generate a compound of Formula (D) or a salt thereof. Any suitable conditions known in the art can be used for steps (a), (b), and (c) of Scheme 2 below, such as those for a coupling reaction between carboxylic acid and sulfonamide or those for an acylation of sulfonamide for step (a), those for hydrolysis of ester for step (b), and those for a nucleophilic reaction of amine for step (c).
[00180] In some embodiments, step (a) of Scheme 2 below is performed in the presence of a base. In some specific embodiments, step (a) is performed in the presence of a non-nucleophilic base. In some embodiments, in step (a), the reaction of a compound of Formula (D) or a salt thereof with a compound of Formula (E) or a salt thereof comprises reacting a compound of Formula (D) or a salt thereof with a coupling reagent, such as carbonyl diimidazole (CDI), and subsequently with a compound of Formula (E) or a salt thereof in the presence of a base, such as a non-nucleophilic base. In some embodiments, a compound of Formula (D) or a salt thereof is reacted with CDI prior to the reaction with a compound of Formula (E) or a salt thereof, and then subsequently with a compound of Formula (E) or a salt thereof in the presence of a base, such as DBU (1,8-diazabicyclo(5.4.0)undec-7-ene).
[00181] In some embodiments, step (b) of Scheme 2 below is performed in the presence of a base. In some embodiments, step (b) is performed in the presence of an aqueous base, such as aqueous hydroxide. In some embodiments, step (b) is performed in the presence of an aqueous metal hydroxide, such as aqueous NaOH. In some embodiments, step (b) of Scheme 2 below is performed in the presence of an acid. In some embodiments, step (b) is performed in the presence of an aqueous acid, such as an aqueous HCl.
[00182] In some embodiments, step (c) of Scheme 2 below is performed in the presence of a base. In some embodiments, step (c) is performed in the presence of a metal carbonate (e.g., Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> or K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>). Scheme 2 [Image disponible dans le document PDF, Image available in the PDF document]
[00183] In some embodiments, disclosed herein is a method of preparing a compound of the following formula (Compound 1): [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. The method comprises reacting a compound of Formula (F-1) or a salt thereof with a compound of Formula (G-1) or a salt thereof, wherein X<com:Sup>a< / com:Sup> is F or Cl, as shown in Scheme 3: Scheme 3 [Image disponible dans le document PDF, Image available in the PDF document]
[00184] Any suitable conditions, such as those for a nucleophilic reaction of amine, known in the art can be used. In some embodiments, the reaction depicted in Scheme 3 is performed in the presence of a base, such as a metal carbonate (e.g., Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> or <com:Math><semantics>K2CO3<annotation encoding="application / x-tex">K_2CO_3< / annotation>< / semantics>< / com:Math>).
[00185] In some embodiments, a salt of compound of Formula (G-1) is employed. In some embodiments, a HCl salt of a compound of Formula (G-1) is employed.
[00186] A compound of Formula (F-1) or a salt thereof and a compound of Formula (G-1) or a salt thereof can be prepared by any suitable method known in the art, for example, those in WO 2016 / 57572 and those in the exemplary syntheses described below in the Examples.
[00187] In some embodiments, as shown in Scheme 4, a compound of Formula (F-1) or a salt thereof, or a deuterated derivative of any of the foregoing is prepared by a method that comprises reacting a compound of Formula (D-1) or a salt thereof with a compound of Formula (E-1) or a salt thereof. In some embodiments, compounds of Formula (D-1) or salts thereof, or their deuterated derivatives are prepared by a method that comprises reacting a compound of Formula (A-1) or a salt thereof with a compound of Formula (B-1) or a salt thereof to generate a compound of formula (C-1) or a salt thereof; and hydrolyzing the <com:Math><semantics>−C(O)ORa<annotation encoding="application / x-tex">-C(O)OR^a< / annotation>< / semantics>< / com:Math> of compound of Formula (C-1) or salt thereof to generate a compound of formula (D-1) or a salt thereof. Any suitable conditions known in the art can be used for steps (a-1), (b-1), and (c-1) of Scheme 4 below, such as those for a coupling reaction between carboxylic acid and sulfonamide or those for an acylation of sulfonamide for step (a-1), those for hydrolysis of ester for step (b-1), and those for a nucleophilic reaction of amine for step (c-1).
[00188] In some embodiments, step (a-1) of Scheme 4 below is performed in the presence of a base. In some embodiments, step (a-1) of Scheme 4 below is performed in the presence of a non-nucleophilic base. In some embodiments, in step (a-1), the reaction of a compound of Formula (D-1) or a salt thereof with a compound of Formula (E-1) or a salt thereof comprises reacting a compound of Formula (D-1) or a salt thereof with a coupling reagent, such as carbonyl diimidazole (CDI), and subsequently with a compound of Formula (E-1) or a salt thereof in the presence of a base, such as a non- nucleophilic base. In some embodiments, (i) a compound of Formula (D-1) or a salt thereof is reacted with CDI prior to the reaction with a compound of Formula (E-1) or a salt thereof, and then subsequently (ii) the reaction product of step (i) is reacted with a compound of Formula (E-1) or a salt thereof in the presence of a base, such as DBU (1,8-Diazabicyclo(5.4.0)undec-7-ene).
[00189] In some embodiments, step (b-1) of Scheme 4 below is performed in the presence of a base. In some embodiments, step (b-1) is performed in the presence of an aqueous base, such as aqueous hydroxide. In some embodiments, step (b-1) is performed in the presence of an aqueous metal hydroxide, such as aqueous NaOH. In some embodiments, step (b-1) of Scheme 4 below is performed in the presence of an acid. In some embodiments, step (b-1) is performed in the presence of an aqueous acid, such as an aqueous HCl.
[00190] In some embodiments, step (c-1) of Scheme 4 below is performed in the presence of a base. In some embodiments, step (c-1) is performed in the presence of a metal carbonate (e.g., Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> or K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub>). Scheme 4 [Image disponible dans le document PDF, Image available in the PDF document]
[00191] In Scheme 4, R<com:Sup>a< / com:Sup> is chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl groups; and each X<com:Sup>a< / com:Sup> is independently F or Cl.
[00192] In some embodiments, methods of preparing a compound of Formulae (I) and (II), wherein X is NH or N(C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl) or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprise reacting a compound of Formula (L) or a salt thereof with NR*3 where R* is H or C1-C4 alkyl, as depicted in Schemes 5 and 6: Scheme 5 [Image disponible dans le document PDF, Image available in the PDF document] (I: where X is NR*) ٠ Scheme 6 [Image disponible dans le document PDF, Image available in the PDF document] (L: where Y<com:Sup>2< / com:Sup> is CH) (II: where X is NR*)
[00193] Any suitable conditions known in the art can be used for the sulfoxamination reaction, for example, for those for electrophilic additions by amines. In some embodiments, the sulfoxamination reaction is performed in the presence of a chlorinating or oxidizing agent, such as N-chlorosuccinimide (NCS).
[00194] In some embodiments, a compound of Formula (L) or a salt thereof is [Image disponible dans le document PDF, Image available in the PDF document] prepared by a method comprising oxidizing the sulfur unit of the a compound of Formula (M) or salt thereof as shown in Scheme 7 below: Scheme 7 [Image disponible dans le document PDF, Image available in the PDF document]
[00195] Any suitable conditions known in the art can be used for the oxidation reaction. In some embodiments, the oxidation is performed in the presence of a peroxycarboxylic acid, such as meta-Chloroperoxybenzoic acid (m-CPBA).
[00196] In some embodiments, a compound of Formula (M) or a salt thereof is prepared by a method comprising reacting a compound of Formula (O) with a compound of Formula (G) or a salt thereof. Any suitable conditions known in the art can be used.
[00197] In some embodiments, a compound of Formula (O) or a salt thereof is prepared by a method comprising reacting a compound of Formula (P) or salt thereof [Image disponible dans le document PDF, Image available in the PDF document] with a phenyl disulfide of Formula (Q): . In some embodiments, a compound of Formula (P) or a salt thereof is prepared by amidating the -C(O)OH group of a compound of Formula (D) or salt thereof. Any suitable conditions known in the art can be used.
[00198] Additional embodiments include: 1. A compound of Formula I: [Image disponible dans le document PDF, Image available in the PDF document] (I), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; - <com:Math><semantics>X<annotation encoding="application / x-tex">X< / annotation>< / semantics>< / com:Math> is chosen from O, NH, and N(C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl) groups; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from halogens, cyano, hydroxy, hydroxymethyl, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen; halogens; cyano; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy; and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8. 2. A compound of Formula II: [Image disponible dans le document PDF, Image available in the PDF document] (II), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: - <com:Math><semantics>X<annotation encoding="application / x-tex">X< / annotation>< / semantics>< / com:Math> is chosen from O, NH, and N(C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl) groups; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxy groups; and C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geminal <com:Math><semantics>𝑹3<annotation encoding="application / x-tex">\mathbf{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from halogens, cyano, hydroxy, hydroxymethyl, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen; halogens; cyano; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy; and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8. 3. A compound of Formula III: [Image disponible dans le document PDF, Image available in the PDF document] (III), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from halogens, cyano, hydroxy, hydroxymethyl, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8. 4. A compound according to any of embodiments 1-3, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; and - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups. 5. A compound according to any of embodiments 1-3, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: [Image disponible dans le document PDF, Image available in the PDF document] - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3< / com:Sub>- C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens, and - each <com:Math><semantics>𝑹2<annotation encoding="application / x-tex">\mathbf{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, OH, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, and halogens; - r is 0; and - q is 0, 1, 2, 3, or 4. 6. A compound according to embodiment 4 having Formula IV or V: [Image disponible dans le document PDF, Image available in the PDF document] (IV) or [Image disponible dans le document PDF, Image available in the PDF document] (V), a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, OH, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, and halogens; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; and - p is 0, 1, or 2. 7. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein p is 0 or 1. 8. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein p is 1. 9. A compound according to any one of embodiments 1-8, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from CH<com:Sub>3< / com:Sub>, OH, F, and OCH<com:Sub>3< / com:Sub>. 10. A compound according to embodiment 9, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein p is 0 or 1. 11. A compound according to embodiment 10, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein: - p is 1; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is methyl; and - <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is methyl. 12. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group. 13. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with a halogenated C<com:Sub>1< / com:Sub> alkyl group. 14. A compound according to embodiment 13, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with a CF<com:Sub>3< / com:Sub> group. 15. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with one or more halogens. 15. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with one or more <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math> alkyl groups. 15. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is a cyclopropyl group substituted with one or more halogens and one or more <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math> alkyl groups. 16. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is a CF<com:Sub>3< / com:Sub> group. 17. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from <com:Math><semantics>ℂ4<annotation encoding="application / x-tex">\mathbb{C}_4< / annotation>< / semantics>< / com:Math> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens. 18. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from <com:Math><semantics>ℂ5<annotation encoding="application / x-tex">\mathbb{C}_5< / annotation>< / semantics>< / com:Math> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens. 19. A compound according to embodiment 18, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein said C<com:Sub>5< / com:Sub> cycloalkyl groups are bicyclic. 20. A compound according to embodiment 6, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from <com:Math><semantics>ℂ7<annotation encoding="application / x-tex">\mathbb{C}_7< / annotation>< / semantics>< / com:Math> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens. 21. A compound according to embodiment 20, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein said C<com:Sub>7< / com:Sub> cycloalkyl groups are bicyclic. 22. A compound according to embodiment 20, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein said C<com:Sub>7< / com:Sub> cycloalkyl groups are tricyclic. 23. A compound having a formula chosen from any one of the formulae depicted in FIG. 1, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 24. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing 25. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 26. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 27. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 28. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 29. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 30. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] , , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 31. A compound according to embodiment 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 32. A compound according to embodiment 1 having any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 33. A compound according to embodiment 1 having any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] - a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 34. A compound according to embodiment 1 having any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] , , [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing. 35. A pharmaceutical composition comprising at least one compound chosen from compounds of any one of embodiments 1-34, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, and optionally one or more of: (a) Compound II: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; (b) Compound III: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and (c) a pharmaceutically acceptable carrier. 36. A method of treating cystic fibrosis comprising administering to a patient in need thereof acompound of any one of embodiments 1-34, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; or a pharmaceutical composition according to embodiment 35. 37. A method of preparing a compound of Formula (X): [Image disponible dans le document PDF, Image available in the PDF document] , a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprising reacting a compound of Formula (F) or a salt thereof with a compound of Formula (G) or a salt thereof to generate said compound of Formula (X) or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing: [Image disponible dans le document PDF, Image available in the PDF document] wherein in each of said formulae: • • - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a <com:Math><semantics>C3−4<annotation encoding="application / x-tex">C_{3-4}< / annotation>< / semantics>< / com:Math> cycloalkyl; - each <com:Math><semantics>𝑹4<annotation encoding="application / x-tex">\mathbf{R}^4< / annotation>< / semantics>< / com:Math> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - X<com:Sup>a< / com:Sup> is F or Cl; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8. 38. The method of embodiment 37, wherein <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N; and each <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> is CH. 39. The method of embodiment 37 or 38, wherein said reacting a compound of Formula (F) or a salt thereof with a compound of Formula (G) or a salt thereof is performed in the presence of a base. 40. The method of any one of embodiments 37-39, wherein a salt of compound of Formula (G) is employed. 41. The method of embodiment 40, wherein said salt of compound of Formula (G) is a HCl salt of a compound of Formula (G). 42. A method of preparing a compound of Formula (F) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , or a deuterated derivative of any of the foregoing, comprising reacting a compound of Formula (D) or salt thereof with a compound of Formula (E) or a salt thereof to generate a compound of Formula (F) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , wherein in each of said formulae: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkoxy groups; and C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - each <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; [Image disponible dans le document PDF, Image available in the PDF document] - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; and - p is 0, 1, or 2. 43. The method of embodiment 42, wherein <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N; and <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> is CH. 44. The method of embodiment 42 or 43, wherein said reacting a compound of Formula (D) or a salt thereof with a compound of Formula (E) or salt thereof is performed in the presence of a base. 45. The method of embodiment 42 or 43, wherein said reacting a compound of Formula (D) or salt thereof with a compound of Formula (E) or salt thereof comprises reacting a compound of Formula (D) with a coupling reagent and subsequently with a compound of Formula (E) in the presence of a base. 46. A method of preparing a compound of the following formula: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, comprising reacting a compound of Formula (F-1) or a salt thereof, wherein X<com:Sup>a< / com:Sup> is F or Cl, with a compound of Formula (G-1) or a salt thereof to generate said compound or a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing: [Image disponible dans le document PDF, Image available in the PDF document] wherein X<com:Sup>a< / com:Sup> in Formula (F-1) is F or Cl. 47. The method of embodiment 46, wherein said reacting a compound of Formula (F-1) or a salt thereof with a compound of Formula (G-1) or a salt thereof is performed in the presence of a base. 48. The method of embodiment 46 or 47, wherein a salt of compound of Formula (G-1) is employed. 49. The method of embodiment 48, wherein said salt of compound of Formula (G-1) is a HCl salt of a compound of Formula (G-1). 50. A method of preparing a compound of Formula (F-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] (F-1) , or a deuterated derivative of any of the foregoing, comprising reacting a compound of Formula (D-1) and a compound of Formula (E-1) to generate a compound of Formula (F-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] > wherein in each said formulae, X<com:Sup>a< / com:Sup> is F or Cl. 51. The method of embodiment 50, wherein said reacting a compound of Formula (D-1) or a salt thereof with a compound of Formula (E-1) or a salt thereof is performed in the presence of a base. 52. The method of embodiment 50, wherein said reacting a compound of Formula (D-1) or a salt thereof with a compound of Formula (E-1) or a salt thereof comprises reacting a compound of Formula (D-1) with a coupling reagent and subsequently with a compound of Formula (E-1) in the presence of a base. 53. A method of preparing a compound of Formula (D) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , or a deuterated derivative of any of the foregoing, comprising: (i) reacting a compound of Formula (A) or a salt thereof with a compound of Formula (B) or a salt thereof to generate a compound of Formula (C) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] (ii) hydrolyzing the –C(O)OR<com:Sup>a< / com:Sup> group of a compound of Formula (C) to generate a compound of Formula (D) or a salt thereof, wherein in each said formulae: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - X<com:Sup>a< / com:Sup> is F or Cl; - k is 0 or 1; - r is 0 or 1; and - m is 0, 1, 2, or 3. 54. The method of embodiment 53, wherein <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N; and <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> is CH. 55. The method of embodiment 53 or 54, wherein the hydrolysis of the -C(O)OR<com:Sup>a< / com:Sup> group is performed in the presence of a base or acid. 56. The method of any one of embodiments 53-55, wherein said reacting a compound of Formula (A) or a salt thereof with a compound of Formula (B) or salt thereof is performed in the presence of a base. 57. The method of any one of embodiments 53-56, wherein R<com:Sup>a< / com:Sup> is ethyl or t-butyl. 58. A method of preparing a compound of Formula (D-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] (D-1) or a deuterated derivative of any of the foregoing, comprising: (i) reacting a compound of Formula (A-1) or a salt thereof and a compound of Formula (B-1) or a salt thereof to generate a compound of Formula (C-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] ; and (ii) hydrolyzing the –C(O)OR<com:Sup>a< / com:Sup> group of a compound of Formula (C-1) or a salt thereof to generate a compound of Formula (D-1) or a salt thereof, wherein in each said formulae, each R<com:Sup>a< / com:Sup> is independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl; and each <com:Math><semantics>Xa<annotation encoding="application / x-tex">X^a< / annotation>< / semantics>< / com:Math> is independently F or Cl. 59. The method of embodiment 58, wherein the hydrolysis of the <com:Math><semantics>−C(O)ORa<annotation encoding="application / x-tex">-C(O)OR^a< / annotation>< / semantics>< / com:Math> group is performed in the presence of a base or acid. 60. The method of 58 or 59, wherein said reacting a compound of Formula (A-1) or a salt thereof and a compound of Formula (B-1) or a salt thereof is performed in the presence of a base. 61. The method of any one of embodiments 58-60, wherein R<com:Sup>a< / com:Sup> is ethyl or t-butyl. 62. A compound of Formula (F) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , or a deuterated derivative of any of the foregoing, wherein in each of said formulae: [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - each <com:Math><semantics>𝑹4<annotation encoding="application / x-tex">\mathbf{R}^4< / annotation>< / semantics>< / com:Math> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>𝑹6<annotation encoding="application / x-tex">\mathbf{R}^6< / annotation>< / semantics>< / com:Math> is chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - X<com:Sup>a< / com:Sup> is F or Cl - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; and - p is 0, 1, or 2. 63. A compound according to embodiment 62, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N; and each <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> is CH. 64. A compound of Formula (F-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] (F-1) , or a deuterated derivative of any of the foregoing, wherein X<com:Sup>a< / com:Sup> is F or Cl. 65. A compound of Formula (C) or (D), or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , or a deuterated derivative of any of the foregoing, wherein in each said formulae: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is independently N and the other is independently CH; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - each R<com:Sup>4< / com:Sup> is independently chosen from halogens; - <com:Math><semantics>𝑹7<annotation encoding="application / x-tex">\mathbf{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - <com:Math><semantics>Ra<annotation encoding="application / x-tex">R^a< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl; - X<com:Sup>a< / com:Sup> is F or Cl; - k is 0 or 1; - r is 0 or 1; and - m is 0, 1, 2, or 3. 66. A compound according to embodiment 65, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein each Y<com:Sup>2< / com:Sup> is independently N; and each Y<com:Sup>1< / com:Sup> is independently CH. 67. A compound according to embodiment 65, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein R<com:Sup>a< / com:Sup> is ethyl or t-butyl. 68. A compound of Formula (C-1) or (D-1), or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(C−1)<annotation encoding="application / x-tex">(C-1)< / annotation>< / semantics>< / com:Math> or (D-1) , or a deuterated derivative of any of the foregoing, wherein R<com:Sup>a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl; and each X<com:Sup>a< / com:Sup> is independently F or Cl. 69. A compound according to embodiment 68, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, wherein R<com:Sup>a< / com:Sup> is ethyl or t-butyl. 70. A compound of Formula (A-1), (C-1) or (D-1), or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] - , or a deuterated derivative of any of the foregoing, wherein R<com:Sup>a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl; and each X<com:Sup>a< / com:Sup> is independently F or Cl. 71. Use of at least one compound chosen from compounds of any one of embodiments 1-34, a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, and optionally one or more of: (a) Compound II: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing; and (b) Compound III: [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable salt thereof, or a deuterated derivative of any of the foregoing, for treating cystic fibrosis. 72. Crystalline Form A of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 73. Crystalline Form A according to embodiment 72 in substantially pure form. 74. Crystalline Form A according to embodiment 72, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 6.6 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.6±0.2<annotation encoding="application / x-tex">7.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9.6±0.2<annotation encoding="application / x-tex">9.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.4±0.2<annotation encoding="application / x-tex">12.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4±0.2<annotation encoding="application / x-tex">16.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.6±0.2<annotation encoding="application / x-tex">18.6 \pm 0.2< / annotation>< / semantics>< / com:Math>. 75. Crystalline Form A according to embodiment 72, characterized by an X-ray powder diffractograph having a signal at at least three two-theta values chosen from 6.6 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9.6±0.2<annotation encoding="application / x-tex">9.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.6±0.2<annotation encoding="application / x-tex">18.6 \pm 0.2< / annotation>< / semantics>< / com:Math>. 76. Crystalline Form A according to embodiment 72, characterized by an X-ray powder diffractograph having a signal at three two-theta values of <com:Math><semantics>6.6±0.2<annotation encoding="application / x-tex">6.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math>. 77. Crystalline Form A according to embodiment 72, characterized by an X-ray powder diffractograph having a signal at six two-theta values of <com:Math><semantics>6.6±0.2<annotation encoding="application / x-tex">6.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9.6±0.2<annotation encoding="application / x-tex">9.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.6±0.2<annotation encoding="application / x-tex">18.6 \pm 0.2< / annotation>< / semantics>< / com:Math>. 78. Crystalline Form A of embodiment 72, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 2. 79. Crystalline Form A of Compound 1 prepared by a process comprising desolvating at least one crystalline form of Compound 1 chosen from Crystalline Form M, Crystalline Form E, Crystalline Form P1, Crystalline Form P2, and Crystalline Form AA2. 80. Crystalline Form A of Compound 1 prepared by a process comprising desolvating at least one solvate chosen from methanol solvates, ethanol solvates, acetic acid solvates, toluene solvates, sulfolane solvates, 1-propanol solvates, 2-propanol solvates, propionic acid solvates, methyl tert-butyl ether solvates, and isobutyric acid solvates of Compound 1 (such as, for example, methanol solvates, ethanol solvates, acetic acid solvates, toluene solvates, sulfolane solvates, propionic acid solvates, methyl tert-butyl ether solvates, and isobutyric acid solvates of Compound 1, further such as, for example, methanol solvates, ethanol solvates, acetic acid solvates, toluene solvates, and sulfolane solvates of Compound 1, and further such as, for example, methanol solvates and ethanol solvates of Compound 1) followed by subjecting the resulting desolvate to vacuum drying at room temperature for 12 to 100 hours. 81. At least one solvate of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] chosen from methanol solvates, ethanol solvates, 1-propanol solvates, 2-propanol solvates, acetic acid solvates, toluene solvates, sulfolane solvates, propionic acid solvates, methyl tert-butyl ether solvates, isobutyric acid solvates, anisole solvates, methylbutyl ketone solvates, and xylene solvates of Compound 1. 83. Crystalline Form M of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 84. Crystalline Form M according to embodiment 83 in substantially pure form. 85. Crystalline Form M according to embodiment 83, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 7.0 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.7±0.2<annotation encoding="application / x-tex">13.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.9±0.2<annotation encoding="application / x-tex">15.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4±0.2<annotation encoding="application / x-tex">16.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>19.3±0.2<annotation encoding="application / x-tex">19.3 \pm 0.2< / annotation>< / semantics>< / com:Math>. 86. Crystalline Form M according to embodiment 83, characterized by an X-ray powder diffractograph having a signal at at least three two-theta values chosen from <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.7±0.2<annotation encoding="application / x-tex">13.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>19.3±0.2<annotation encoding="application / x-tex">19.3 \pm 0.2< / annotation>< / semantics>< / com:Math>. 87. Crystalline Form M according to embodiment 83, characterized by an X-ray powder diffractograph having a signal at three two-theta values of <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8±<annotation encoding="application / x-tex">17.8 \pm< / annotation>< / semantics>< / com:Math> 0.2, and <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>. 88. Crystalline Form M according to embodiment 83, characterized by an X-ray powder diffractograph having a signal at six two-theta values of <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.7±0.2<annotation encoding="application / x-tex">13.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>19.3±0.2<annotation encoding="application / x-tex">19.3 \pm 0.2< / annotation>< / semantics>< / com:Math>. 89. Crystalline Form M of embodiment 83, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 13. 90. Crystalline Form E of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 91. Crystalline Form E according to embodiment 90 in substantially pure form. 92. Crystalline Form E according to embodiment 90, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 7.0 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.2±0.2<annotation encoding="application / x-tex">11.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.1±0.2<annotation encoding="application / x-tex">14.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.1±0.2<annotation encoding="application / x-tex">15.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±0.2<annotation encoding="application / x-tex">16.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.9±0.2<annotation encoding="application / x-tex">18.9 \pm 0.2< / annotation>< / semantics>< / com:Math>. 93. Crystalline Form E according to embodiment 90, characterized by an X-ray powder diffractograph having a signal at at least three two-theta values chosen from <com:Math><semantics>11.2±0.2<annotation encoding="application / x-tex">11.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.1±0.2<annotation encoding="application / x-tex">15.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±0.2<annotation encoding="application / x-tex">16.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>. 94. Crystalline Form E according to embodiment 90, characterized by an X-ray powder diffractograph having a signal at three two-theta values of <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±<annotation encoding="application / x-tex">16.1 \pm< / annotation>< / semantics>< / com:Math> 0.2, and <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>. 95. Crystalline Form E according to embodiment 90, characterized by an X-ray powder diffractograph having a signal at six two-theta values of <com:Math><semantics>11.2±0.2<annotation encoding="application / x-tex">11.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.1±0.2<annotation encoding="application / x-tex">15.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±0.2<annotation encoding="application / x-tex">16.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>. 96. Crystalline Form E of embodiment 90, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 14. 97. A method of preparing crystalline Form A of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 1, comprising stirring a solution or suspension of Compound 1 in a solvent system at a temperature in a range from 50 °C to 85 °C. 98. A method of preparing crystalline Form A of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 1, comprising desolvating a solvate of Compound 1 chosen from methanol solvates, ethanol solvates, 1-propanol solvates, 2-propanol solvates, acetic acid solvates, toluene solvates, sulfolane solvates, propionic acid solvates, methyl tert-butyl ether solvates, isobutyric acid solvates, anisole solvates, methylbutyl ketone solvates, and xylene solvates of Compound 1. 99. A crystalline Form X of a potassium salt of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 100. Crystalline Form X according to embodiment 99 in substantially pure form. 101. Crystalline Form X according to embodiment 99, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 4.9 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9±0.2<annotation encoding="application / x-tex">5.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.1±0.2<annotation encoding="application / x-tex">8.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.5±0.2<annotation encoding="application / x-tex">8.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>10.3±0.2<annotation encoding="application / x-tex">10.3 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.0±0.2<annotation encoding="application / x-tex">13.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.9±0.2<annotation encoding="application / x-tex">13.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.6±0.2<annotation encoding="application / x-tex">14.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.0±0.2<annotation encoding="application / x-tex">17.0 \pm 0.2< / annotation>< / semantics>< / com:Math>. 102. Crystalline Form X according to embodiment 99, characterized by an X-ray powder diffractograph having a signal at at least three two-theta values chosen from 4.9 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, 5.9 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, 8.1 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, 13.0 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, 13.9 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, and 17.0 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>. 103. Crystalline Form X according to embodiment 99, characterized by an X-ray powder diffractograph having a signal at three two-theta values of <com:Math><semantics>4.9±0.2<annotation encoding="application / x-tex">4.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9±0.2<annotation encoding="application / x-tex">5.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>13.0±0.2<annotation encoding="application / x-tex">13.0 \pm 0.2< / annotation>< / semantics>< / com:Math>. 104. Crystalline Form X according to embodiment 99, characterized by an X-ray powder diffractograph having a signal at six two-theta values of <com:Math><semantics>4.9±0.2<annotation encoding="application / x-tex">4.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9±0.2<annotation encoding="application / x-tex">5.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.1<annotation encoding="application / x-tex">8.1< / annotation>< / semantics>< / com:Math> <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.0±0.2<annotation encoding="application / x-tex">13.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.9±0.2<annotation encoding="application / x-tex">13.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.0±0.2<annotation encoding="application / x-tex">17.0 \pm 0.2< / annotation>< / semantics>< / com:Math>. 105. Crystalline Form X of embodiment 99, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 15. 106. A crystalline Form Y of a sodium salt of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 107. Crystalline Form Y according to embodiment 106 in substantially pure form. 108. Crystalline Form Y according to embodiment 106, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 3.5 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.2±0.2<annotation encoding="application / x-tex">14.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.4±0.2<annotation encoding="application / x-tex">15.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.6±0.2<annotation encoding="application / x-tex">16.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.0±0.2<annotation encoding="application / x-tex">18.0 \pm 0.2< / annotation>< / semantics>< / com:Math>. 109. Crystalline Form Y according to embodiment 106, characterized by an X-ray powder diffractograph having a signal at at least three two-theta values chosen from 3.5 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.2±0.2<annotation encoding="application / x-tex">14.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.0±0.2<annotation encoding="application / x-tex">18.0 \pm 0.2< / annotation>< / semantics>< / com:Math> 110. Crystalline Form Y according to embodiment 106, characterized by an X-ray powder diffractograph having a signal at three two-theta values of <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>. 111. Crystalline Form Y according to embodiment 106, characterized by an X-ray powder diffractograph having a signal at six two-theta values of <com:Math><semantics>3.5±0.2<annotation encoding="application / x-tex">3.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.2±0.2<annotation encoding="application / x-tex">14.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.0±0.2<annotation encoding="application / x-tex">18.0 \pm 0.2< / annotation>< / semantics>< / com:Math>. 112. Crystalline Form Y of embodiment 106, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 16. 113. A solid dispersion comprising Compound 1 and a polymer. 114. The solid dispersion of embodiment 113, comprising 50 wt% of Compound 1 and 50 wt% of a polymer by the total weight of the solid dispersion or 80 wt% of Compound 1 and 20 wt% of a polymer by the total weight of the solid dispersion. 115. The solid dispersion of embodiment 113 or 114, wherein the polymer is a hypromellose acetate succinate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, or polyvinylpyrrolidone. 116. A pharmaceutical formulation comprising at least one crystalline form according to any one of embodiments 72 - 96 and 99 - 112, and a pharmaceutically acceptable carrier. 117. A method of treating cystic fibrosis comprising administering to a patient in need thereof at least one crystalline form according to any one of embodiments 72-96, and 199 - 112. 118. A method of treating cystic fibrosis comprising administering to a patient in need thereof a solid dispersion according to any one of embodiments 113 - 115. 119. Crystalline Form P2 of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 120. Crystalline Form P2 according to embodiment 119 in substantially pure form. 121. Crystalline Form P2 according to embodiment 119, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>10.2±0.2<annotation encoding="application / x-tex">10.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±0.2<annotation encoding="application / x-tex">12.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.9±0.2<annotation encoding="application / x-tex">12.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.0±0.2<annotation encoding="application / x-tex">15.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.9±0.2<annotation encoding="application / x-tex">15.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.2±0.2<annotation encoding="application / x-tex">16.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.5±0.2<annotation encoding="application / x-tex">16.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, and 17.6 <com:Math><semantics>±0.2<annotation encoding="application / x-tex">\pm 0.2< / annotation>< / semantics>< / com:Math>. 122. Crystalline Form P2 according to embodiment 119, characterized by an X-ray powder diffractograph having a signal at at least three two-theta values chosen from <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±0.2<annotation encoding="application / x-tex">12.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.9±0.2<annotation encoding="application / x-tex">12.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.0±0.2<annotation encoding="application / x-tex">15.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.5±0.2<annotation encoding="application / x-tex">16.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.6±0.2<annotation encoding="application / x-tex">17.6 \pm 0.2< / annotation>< / semantics>< / com:Math>. 123. Crystalline Form P2 according to embodiment 119, characterized by an X-ray powder diffractograph having a signal at three two-theta values of <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±0.2<annotation encoding="application / x-tex">12.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.6±0.2<annotation encoding="application / x-tex">17.6 \pm 0.2< / annotation>< / semantics>< / com:Math>. 124. Crystalline Form P2 according to embodiment 119, characterized by an X-ray powder diffractograph having a signal at six two-theta values of <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±0.2<annotation encoding="application / x-tex">12.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.9±<annotation encoding="application / x-tex">12.9 \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.0±0.2<annotation encoding="application / x-tex">15.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.5±0.2<annotation encoding="application / x-tex">16.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.6±0.2<annotation encoding="application / x-tex">17.6 \pm 0.2< / annotation>< / semantics>< / com:Math>. 125. Crystalline Form P2 of embodiment 119, characterized by an X-ray powder diffractogram substantially similar to that in FIG. 17. Other embodiments include: A. Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] . B. A pharmaceutically acceptable salt of Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] • C. A pharmaceutical composition comprising: (i) Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] (ii) a pharmaceutically acceptable carrier. D. The pharmaceutical composition of embodiment C further comprising Compound II: [Image disponible dans le document PDF, Image available in the PDF document] E. The pharmaceutical composition of embodiment C further comprising a pharmaceutically acceptable salt of Compound II: [Image disponible dans le document PDF, Image available in the PDF document] F. The pharmaceutical composition of embodiment C further comprising Compound III: [Image disponible dans le document PDF, Image available in the PDF document] G. The pharmaceutical composition of embodiment C further comprising a pharmaceutically acceptable salt of Compound III: [Image disponible dans le document PDF, Image available in the PDF document] H. The pharmaceutical composition of embodiment D further comprising Compound III: [Image disponible dans le document PDF, Image available in the PDF document] I. The pharmaceutical composition of embodiment D further comprising a pharmaceutically acceptable salt of Compound III: [Image disponible dans le document PDF, Image available in the PDF document] J. The pharmaceutical composition of embodiment E further comprising Compound III: [Image disponible dans le document PDF, Image available in the PDF document] K. The pharmaceutical composition of embodiment E further comprising a pharmaceutically acceptable salt of Compound III: [Image disponible dans le document PDF, Image available in the PDF document] L. A pharmaceutical composition comprising: (A) a pharmaceutically acceptable salt of Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] (B) a pharmaceutically acceptable carrier. M. The pharmaceutical composition of embodiment L further comprising Compound II: [Image disponible dans le document PDF, Image available in the PDF document] N. The pharmaceutical composition of embodiment L further comprising a pharmaceutically acceptable salt of Compound II: [Image disponible dans le document PDF, Image available in the PDF document] O. The pharmaceutical composition of embodiment L further comprising Compound III: [Image disponible dans le document PDF, Image available in the PDF document] P. The pharmaceutical composition of embodiment L further comprising a pharmaceutically acceptable salt of Compound III: [Image disponible dans le document PDF, Image available in the PDF document] Q. The pharmaceutical composition of embodiment M further comprising Compound III: [Image disponible dans le document PDF, Image available in the PDF document] R. The pharmaceutical composition of embodiment M further comprising a pharmaceutically acceptable salt of Compound III: [Image disponible dans le document PDF, Image available in the PDF document] S. The pharmaceutical composition of embodiment M further comprising Compound III: [Image disponible dans le document PDF, Image available in the PDF document] T. The pharmaceutical composition of embodiment M further comprising a pharmaceutically acceptable salt of Compound III: [Image disponible dans le document PDF, Image available in the PDF document] U. A method of treating cystic fibrosis comprising administering to a patient in need thereof Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] ٠ V. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutically acceptable salt of Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] ٠ W. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition comprising: (A) Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] (B) a pharmaceutically acceptable carrier. X. A method of treating cystic fibrosis comprising administering to a patient in need thereof a pharmaceutical composition comprising: a pharmaceutically acceptable salt of Compound 1 of the formula [Image disponible dans le document PDF, Image available in the PDF document] a pharmaceutically acceptable carrier.
[00199] General Experimental Procedures
[00200] The definitions of certain abbreviations for the Examples below are summarized below: Boc anhydride (Boc)<com:Sub>2< / com:Sub>O): di-tert-butyl dicarbonate CDI: carbonyl diimidazole DABCO<com:Sup>TM< / com:Sup>: 1,4-diazabicyclo[2.2.2]octane DBU: 1,8-diazabicyclo(5.4.0)undec-7-ene DCM: dichloromethane DIAD: diisopropyl azodicarboxylate DIEA (DIPEA; N,N-diisopropylethylamine) DMA: N,N-Dimethylacetamide DMF: N,N-dimethylformamide DMSO: dimethyl sulfoxide Et<com:Sub>2< / com:Sub>O: diethyl ether EtOH: ethanol HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate IPA: isoproanol MeOH: methanol NMP: N-methyl-2-pyrrolidone MTBE: methyl tert-butyl ether TBS-Cl: tert-Butyldimethylsilyl chloride TFA: trifluoroacetic acid THF: tetrahydrofuran) p-TsOH: p-Toluenesulfonic Acid TPPO-DIAD complex: a complex of triphenylphosphine oxide with diisopropyl azodicarboxylate
[00201] Reagents and starting materials were obtained by commercial sources unless otherwise stated and were used without purification. Proton and carbon NMR spectra were acquired on either of a Bruker Biospin DRX 400 MHz FTNMR spectrometer operating at a <com:Sup>1< / com:Sup>H and <com:Sup>13< / com:Sup>C resonant frequency of 400 and 100 MHz respectively, or on a 300 MHz NMR spectrometer. One dimensional proton and carbon spectra were acquired using a broadband observe (BBFO) probe with 20 Hz sample rotation at 0.1834 and 0.9083 Hz / Pt digital resolution respectively. All proton and carbon spectra were acquired with temperature control at 30°C using standard, previously published pulse sequences and routine processing parameters. Final purity of compounds was determined by reversed phase UPLC using an Acquity<com:Sup>TM< / com:Sup> UPLC BEH <com:Math><semantics>C18<annotation encoding="application / x-tex">C_{18}< / annotation>< / semantics>< / com:Math> column (50 × 2.1 mm, 1.7 µm particle) made by Waters (pn: 186002350), and a dual gradient run from 1-99% mobile phase B over 3.0 minutes. Mobile phase <com:Math><semantics>A=H2O<annotation encoding="application / x-tex">A = H_2O< / annotation>< / semantics>< / com:Math> (0.05 % <com:Math><semantics>CF3CO2H<annotation encoding="application / x-tex">CF_3CO_2H< / annotation>< / semantics>< / com:Math>). Mobile phase <com:Math><semantics>B=CH3CN<annotation encoding="application / x-tex">B = CH_3CN< / annotation>< / semantics>< / com:Math> (0.035 % <com:Math><semantics>CF3CO2H<annotation encoding="application / x-tex">CF_3CO_2H< / annotation>< / semantics>< / com:Math>). Flow rate = 1.2 mL / min, injection volume = 1.5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>L, and column temperature = 60 °C. Final purity was calculated by averaging the area under the curve (AUC) of two UV traces (220 nm, 254 nm). Low-resolution mass spectra were reported as [M+H]<com:Sup>+< / com:Sup> species obtained using a single quadrupole mass spectrometer equipped with an electrospray ionization (ESI) source capable of achieving a mass accuracy of 0.1 Da and a minimum resolution of 1000 (no units on resolution) across the detection range. Optical purity of methyl (2S)- 2,4-dimethyl-4-nitro-pentanoate was determined using chiral gas chromatography (GC) analysis on an Agilent 7890A / MSD 5975C instrument, using a Restek Rt-βDEXcst (30m x 0.25mm x 0.25mm x f) column, with a 2.0 mL / min flow rate (H<com:Sub>2< / com:Sub> carrier gas), at an injection temperature of 220°C and an oven temperature of 120°C, 15 minutes.
[00202] Powder X-ray Diffraction
[00203] The powder x-ray diffraction measurements were performed using PANalytical's X-pert Pro diffractometer at room temperature with copper radiation (1.54060 Å). The incident beam optic was comprised of a variable divergence slit to ensure a constant illuminated length on the sample and on the diffracted beam side; a fast linear solid state detector was used with an active length of 2.12 degrees 2 theta measured in a scanning mode. The powder sample was packed on the indented area of a zero background silicon holder and spinning was performed to achieve better statistics. A symmetrical scan was measured from <com:Math><semantics>4−40<annotation encoding="application / x-tex">4-40< / annotation>< / semantics>< / com:Math> degrees 2 theta with a step size of 0.017 degrees and a scan step time of 15.5s.
[00204] Figure 2 shows the XRPD spectrum of Form A of Compound 1. The single crystal structure of Form A has been elucidated. The crystal structure confirms the absolute configuration of the molecule, and the calculated XRPD patterns show good agreement with the experimental patterns. Form A of Compound 1 forms as an orthorhombic unit cell of <com:Math><semantics>P212121<annotation encoding="application / x-tex">P2_12_12_1< / annotation>< / semantics>< / com:Math>, a=15.74 b=22.86 c=26.59 (angstroms), <com:Math><semantics>α=β=γ=90<annotation encoding="application / x-tex">\alpha = \beta = \gamma = 90< / annotation>< / semantics>< / com:Math>, Z=12 V= 9575 Flack =0.08. One of ordinary skill in the art would recognize that there may be variation in these crystal parameters depending, for example, on the temperature, pressure, or instrument to instrument variability.
[00205] Figure 3 shows an experimental XRPD of Form A of Compound 1 (top) compared to a calculated XRD (bottom), which is calculated from the single crystal data. Figure 3 shows an overlay of the experimental and calculated XRPD of Form A of Compound 1 from Figure 3.
[00206] Figure 5 shows the XRPD spectrum of amorphous Compound 1 prepared by spray dried dispersion (SDD) of 50 wt% Compound 1 in HPMCAS-HG.
[00207] Modulated Differential Scanning Calorimetry (MDSC)
[00208] MDSC was used to determine the glass transition temperature of the amorphous material. MDSC was performed using TA Discovery DSC differential scanning calorimeter (TA Instruments, New Castle, DE). The instrument was calibrated with indium. Samples of approximately 1-3 mg were weighed into hermetic pans that were crimped using lids with one hole. The MDSC sample was scanned from -20°C to 200°C at a heating rate of 2°C / min with + / - 1°C of modulation within 1 minute. Data was collected and analyzed by TA Instruments Trios Software (TA Instruments, New Castle, DE).
[00209] Figure 6 shows a MDSC spectrum of a spray dried dispersion (SDD) of 50 wt% Compound 1 in HPMCAS-HG, and shows that the SDD has a midpoint temperature of about 106°C.
[00210] Single-Crystal Analysis
[00211] X-ray diffraction data were acquired at 100K or 298K on a Bruker diffractometer equipped with Mo K<com:Sub>x< / com:Sub> radiation (<com:Math><semantics>λ=0.71073 Å<annotation encoding="application / x-tex">\lambda = 0.71073 \text{ Å}< / annotation>< / semantics>< / com:Math>) or Cu K<com:Sub>x< / com:Sub> radiation (<com:Math><semantics>λ=<annotation encoding="application / x-tex">\lambda =< / annotation>< / semantics>< / com:Math> 1.5478) and an CCD detector. The structure was solved and refined using SHELX program (Sheldrick, G.M., Acta Cryst., (2008) A64, 112-122).
[00212] Thermogravimetric Analysis (TGA)
[00213] TGA was used to investigate the presence of residual solvents in the lots characterized, and identify the temperature at which decomposition of the sample occurs. TGA data were collected on a TA Discovery Thermogravimetric Analyzer or equivalent instrumentation. A sample with weight of approximately 1-5 mg was scanned from 25 °C to 350 °C at a heating rate of 10 °C / min. Data were collected and analyzed by Trios software (TA Instruments, New Castle, DE) or collected by Thermal Advantage Q SeriesTM software and analyzed by Universal Analysis software (TA Instruments, New Castle, DE).
[00214] Differential Scanning Calorimetry (DSC)
[00215] DSC data were acquired using a TA Instruments Q2000 or equivalent instrumentation. A sample with a weight between 1 and 10 mg was weighed into an aluminum pan. This pan was placed in the sample position in the calorimeter cell. An empty pan was placed in the reference position. The calorimeter cell was closed and a flow of nitrogen was passed through the cell. The heating program was set to heat the sample at a heating rate of 10° C. / min to a temperature of 200-350° C. When the run was completed, the data were analyzed using the DSC analysis program in the system software. The observed endo- and exotherms were integrated between baseline temperature points that were above and below the temperature range over which the endotherm was observed. The data reported were the onset of decomposition temperature, peak temperature and enthalpy.
[00216] Synthetic Examples
[00217] Synthesis of Compound II: (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)- N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol- 5-yl)cyclopropanecarboxamide [Image disponible dans le document PDF, Image available in the PDF document]
[00218] Step 1: (R)-Benzyl 2-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6- fluoro-5-nitro-1H-indol-2-yl)-2-methylpropanoate and ((S)-2,2-Dimethyl-1,3- dioxolan-4-yl)methyl 2-(1-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5- nitro-1H-indol-2-yl)-2-methylpropanoate
[00219] Cesium carbonate (8.23 g, 25.3 mmol) was added to a mixture of benzyl 2-(6- fluoro-5-nitro-1H-indol-2-yl)-2-methylpropanoate (3.0 g, 8.4 mmol) and (S)-(2,2- dimethyl-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate (7.23 g, 25.3 mmol) in DMF (N,N-dimethylformamide) (17 mL). The reaction was stirred at 80 °C for 46 hours under a nitrogen atmosphere. The mixture was then partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined ethyl acetate layers were washed with brine, dried over MgSO<com:Sub>4< / com:Sub>, filtered and concentrated. The crude product, a viscous brown oil which contains both of the products shown above, was taken directly to the next step without further purification. (R)-Benzyl 2-(1- ((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2- methylpropanoate, ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 470.2, found 471.5 (M+1)<com:Sup>+< / com:Sup>. Retention time 2.20 minutes. ((S)-2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 2-(1-(((R)-2,2-dimethyl-1,3- dioxolan-4-yl)methyl)-6-fluoro-5-nitro-1H-indol-2-yl)-2-methylpropanoate, ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 494.5, found 495.7 (M+1)<com:Sup>+< / com:Sup>. Retention time 2.01 minutes.
[00220] Step 2: (R)-2-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5- nitro-1H-indol-2-yl)-2-methylpropan-1-ol
[00221] The crude reaction mixture obtained in step (A) was dissolved in THF (tetrahydrofuran) (42 mL) and cooled in an ice-water bath. LiAlH<com:Sub>4< / com:Sub> (16.8 mL of 1 M solution, 16.8 mmol) was added drop-wise. After the addition was complete, the mixture was stirred for an additional 5 minutes. The reaction was quenched by adding water (1 mL), 15% NaOH solution (1 mL) and then water (3 mL). The mixture was filtered over Celite<com:Sup>TM< / com:Sup>, and the solids were washed with THF and ethyl acetate. The filtrate was concentrated and purified by column chromatography (30-60% ethyl acetate- hexanes) to obtain (R)-2-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-nitro- 1H-indol-2-yl)-2-methylpropan-1-ol as a brown oil (2.68g, 87 % over 2 steps). ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 366.4, found 367.3 (M+1)<com:Sup>+< / com:Sup>. Retention time 1.68 minutes. <com:Sup>1< / com:Sup>H NMR (400) MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.34 (d, J = 7.6 Hz, 1H), 7.65 (d, J = 13.4 Hz, 1H), 6.57 (s, 1H), <com:Math><semantics>4.94<annotation encoding="application / x-tex">4.94< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=5.4<annotation encoding="application / x-tex">J = 5.4< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.64−4.60<annotation encoding="application / x-tex">4.64 - 4.60< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.52−4.42<annotation encoding="application / x-tex">4.52 - 4.42< / annotation>< / semantics>< / com:Math>(m, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.16−4.14<annotation encoding="application / x-tex">4.16 - 4.14< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), 3.76 - 3.74 (m, 1H), 3.63 - 3.53 (m, 2H), 1.42 (s, 3H), 1.38 - 1.36 (m, 6H) and 1.19 (s, 3H) ppm. (DMSO is dimethylsulfoxide).
[00222] Step 3: (R)-2-(5-amino-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6- fluoro-1H-indol-2-yl)-2-methylpropan-1-ol
[00223] (R)-2-(1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-5-nitro-1H-indol- 2-yl)-2-methylpropan-1-ol (2.5 g, 6.82 mmol) was dissolved in ethanol (70 mL) and the reaction was flushed with <com:Math><semantics>N2<annotation encoding="application / x-tex">N_2< / annotation>< / semantics>< / com:Math>. Then Pd-C (250 mg, 5% wt) was added. The reaction was flushed with nitrogen again and then stirred under H<com:Sub>2< / com:Sub> (atm). After 2.5 hours only partial conversion to the product was observed by LCMS. The reaction was filtered through Celite and concentrated. The residue was re-subjected to the conditions above. After 2 hours LCMS indicated complete conversion to product. The reaction mixture was filtered through Celite. The filtrate was concentrated to yield the product (1.82 g, 79 %). ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 336.2, found 337.5 (M+1)<com:Sup>+< / com:Sup>. Retention time 0.86 minutes. <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400 MHz, DMSO-d6)δ7.17 (d, J=12.6 Hz,1H),6.76 (d, J=9.0 Hz,1H),6.03 (s, d)<annotation encoding="application / x-tex">(400 \text{ MHz}, \text{ DMSO-}d6) \delta 7.17 \text{ (d, J} = 12.6 \text{ Hz}, 1\text{H}), 6.76 \text{ (d, J} = 9.0 \text{ Hz}, 1\text{H}), 6.03 \text{ (s, d)}< / annotation>< / semantics>< / com:Math> 1H), <com:Math><semantics>4.79−4.76<annotation encoding="application / x-tex">4.79 - 4.76< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>4.46<annotation encoding="application / x-tex">4.46< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>4.37−4.31<annotation encoding="application / x-tex">4.37 - 4.31< / annotation>< / semantics>< / com:Math> (m, 3H), <com:Math><semantics>4.06<annotation encoding="application / x-tex">4.06< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=6.1<annotation encoding="application / x-tex">J = 6.1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.3<annotation encoding="application / x-tex">8.3< / annotation>< / semantics>< / com:Math> Hz, 1H), 3.70 - 3.67 (m, 1H), 3.55 - 3.52 (m, 2H), 1.41 (s, 3H), 1.32 (s, 6H) and 1.21 (s, 3H) ppm.
[00224] Step 4: (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-((2,2-dimethyl- 1,3-dioxolan-4-yl)methyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5- yl)cyclopropanecarboxamide
[00225] DMF (3 drops) was added to a stirring mixture of 1-(2,2- difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (1.87 g, 7.7 mmol) and thionyl chloride (1.30 mL, 17.9 mmol). After 1 hour a clear solution had formed. The solution was concentrated under vacuum and then toluene (3 mL) was added and the mixture was concentrated again. The toluene step was repeated once more and the residue was placed on high vacuum for 10 minutes. The acid chloride was then dissolved in dichloromethane (10 mL) and added to a mixture of (R)-2-(5-amino-1- ((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-6-fluoro-1H-indol-2-yl)-2-methylpropan-1-ol (1.8 g, 5.4 mmol) and triethylamine (2.24 mL, 16.1 mmol) in dichloromethane (45 mL). The reaction was stirred at room temperature for 1 hour. The reaction was washed with 1N HCl solution, saturated NaHCO<com:Sub>3< / com:Sub> solution and brine, dried over MgSO<com:Sub>4< / com:Sub> and concentrated to yield the product (3g, 100%). ESI-MS m / z calc. 560.6, found 561.7 (M+1)<com:Sup>+< / com:Sup>. Retention time 2.05 minutes. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.53 (s, 1H), 7.42 - 7.40 (m, 2H), 7.34 - 7.30 (m, 3H), 6.24 (s, 1H), 4.51 - 4.48 (m, 1H), <com:Math><semantics>4.39−4.34<annotation encoding="application / x-tex">4.39 - 4.34< / annotation>< / semantics>< / com:Math> (m,2H), <com:Math><semantics>4.08<annotation encoding="application / x-tex">4.08< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.3<annotation encoding="application / x-tex">8.3< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>3.69<annotation encoding="application / x-tex">3.69< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>3.58−3.51<annotation encoding="application / x-tex">3.58 - 3.51< / annotation>< / semantics>< / com:Math> (m, 2H), 1.48 - 1.45 (m, 2H), 1.39 (s, 3H), 1.34 - 1.33 (m, 6H), 1.18 (s, 3H) and 1.14 - 1.12 (m, 2H) ppm.
[00226] Step 5: (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3- dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5- yl)cyclopropanecarboxamide
[00227] <com:Math><semantics>(R)−1−(2,2−diffuorobenzo[d][1,3]dioxol−5−yl)−N−(1−((2,2−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl−1,3−dimethyl<annotation encoding="application / x-tex">(R)-1-(2,2-diffuorobenzo[d][1,3]dioxol-5-yl)-N-(1-((2,2-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl-1,3-dimethyl< / annotation>< / semantics>< / com:Math> dioxolan-4-yl)methyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5- yl)cyclopropanecarboxamide (3.0 g, 5.4 mmol) was dissolved in methanol (52 mL). Water (5.2 mL) was added followed by p-TsOH.H<com:Sub>2< / com:Sub>O (p-toluenesulfonic acid hydrate) (204 mg, 1.1 mmol). The reaction was heated at 80 °C for 45 minutes. The solution was concentrated and then partitioned between ethyl acetate and saturated NaHCO<com:Sub>3< / com:Sub> solution. The ethyl acetate layer was dried over MgSO<com:Sub>4< / com:Sub> and concentrated. The residue was purified by column chromatography (50-100 % ethyl acetate - hexanes) to yield the product. (1.3 g, 47 %, ee >98% by SFC). ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 520.5, found 521.7 (M+1)<com:Sup>+< / com:Sup>. Retention time 1.69 minutes. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.53 (s, 1H), <com:Math><semantics>7.42−7.38<annotation encoding="application / x-tex">7.42 - 7.38< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>7.33−7.30<annotation encoding="application / x-tex">7.33 - 7.30< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>6.22<annotation encoding="application / x-tex">6.22< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>5.01<annotation encoding="application / x-tex">5.01< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=5.2<annotation encoding="application / x-tex">J = 5.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.90 (t, J = 5.5 Hz, 1H),4.75 (t, J = 5.8 Hz, 1H),4.40 (dd, J = 2.6, 15.1 Hz, 1H),4.10<annotation encoding="application / x-tex">4.90 \text{ (t, J = 5.5 Hz, 1H)}, 4.75 \text{ (t, J = 5.8 Hz, 1H)}, 4.40 \text{ (dd, J = 2.6, 15.1 Hz, 1H)}, 4.10< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(dd,J=8.7,15.1Hz,1H),3.90(s,1H),3.65−3.54(m,2H),3.48−3.33(m,2H),1.48−<annotation encoding="application / x-tex">(dd, J = 8.7, 15.1 Hz, 1H), 3.90 (s, 1H), 3.65 - 3.54 (m, 2H), 3.48 - 3.33 (m, 2H), 1.48 -< / annotation>< / semantics>< / com:Math> 1.45 (m, 2H), 1.35 (s, 3H), 1.32 (s, 3H) and 1.14 - 1.11 (m, 2H) ppm.
[00228] Synthesis of Compound III: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide
[00229] Part A: Synthesis of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document]
[00230] Step 1: 2-Phenylaminomethylene-malonic acid diethyl ester
[00231] A mixture of aniline (25.6 g, 0.275 mol) and diethyl 2- (ethoxymethylene)malonate (62.4 g, 0.288 mol) was heated at 140-150 °C for 2 h. The mixture was cooled to room temperature and dried under reduced pressure to afford 2- phenylaminomethylene-malonic acid diethyl ester as a solid, which was used in the next step without further purification. <com:Sup>1< / com:Sup>H NMR (DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 11.00 (d, 1H), 8.54 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 13.6 Hz, 1H), 7.36-7.39 (m, 2H), 7.13-7.17 (m, 3H), 4.17-4.33 (m, 4H), 1.18-1.40 (m, 6H).
[00232] Step 2: 4-Hydroxyquinoline-3-carboxylic acid ethyl ester
[00233] A 1 L three-necked flask fitted with a mechanical stirrer was charged with 2- phenylaminomethylene-malonic acid diethyl ester (26.3 g, 0.100 mol), polyphosphoric acid (270 g) and phosphoryl chloride (750 g). The mixture was heated to 70 °C and stirred for 4 h. The mixture was cooled to room temperature and filtered. The residue was treated with aqueous Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> solution, filtered, washed with water and dried. 4- Hydroxyquinoline-3-carboxylic acid ethyl ester was obtained as a pale brown solid (15.2 g, 70%). The crude product was used in next step without further purification.
[00234] Step 3: 4-Oxo-1,4-dihydroquinoline-3-carboxylic acid
[00235] 4-Hydroxyquinoline-3-carboxylic acid ethyl ester (15 g, 69 mmol) was suspended in sodium hydroxide solution (2N, 150 mL) and stirred for 2 h at reflux. After cooling, the mixture was filtered, and the filtrate was acidified to pH 4 with 2N HCl. The resulting precipitate was collected via filtration, washed with water and dried under vacuum to give 4-oxo-1,4-dihydroquinoline-3-carboxylic acid as a pale white solid (10.5 g, 92 %). <com:Sup>1< / com:Sup>H NMR (DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 15.34 (s, 1 H), 13.42 (s, 1 H), 8.89 (s, 1H), <com:Math><semantics>8.28 (d, J=8.0 Hz, 1H),7.88 (m, 1H),7.81 (d, J=8.4 Hz, 1H),7.60 (m, 1H).<annotation encoding="application / x-tex">8.28 \text{ (d, } J = 8.0 \text{ Hz, 1H)}, 7.88 \text{ (m, 1H)}, 7.81 \text{ (d, J} = 8.4 \text{ Hz, 1H)}, 7.60 \text{ (m, 1H)}.< / annotation>< / semantics>< / com:Math>
[00236] Part B: Synthesis of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4- dihydroquinoline-3-carboxamide [Image disponible dans le document PDF, Image available in the PDF document]
[00237] Step 1: Carbonic acid 2,4-di-tert-butyl-phenyl ester methyl ester
[00238] Methyl chloroformate (58 mL, 750 mmol) was added dropwise to a solution of 2,4-di-tert-butyl-phenol (103.2 g, 500 mmol), Et<com:Sub>3< / com:Sub>N (139 mL, 1000 mmol) and DMAP (3.05 g, 25 mmol) in dichloromethane (400 mL) cooled in an ice-water bath to 0 °C. The mixture was allowed to warm to room temperature while stirring overnight, then filtered through silica gel (approx. 1L) using 10% ethyl acetate – hexanes (~ 4 L) as the eluent. The combined filtrates were concentrated to yield carbonic acid 2,4-di- tert-butyl-phenyl ester methyl ester as a yellow oil (132 g, quant.). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.35 (d, J = 2.4 Hz, 1H), 7.29 (dd, J = 8.5, 2.4 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 3.85 (s, 3H), 1.30 (s, 9H), 1.29 (s, 9H).
[00239] Step 2: Carbonic acid 2,4-di-tert-butyl-5-nitro-phenyl ester methyl ester and Carbonic acid 2,4-di-tert-butyl-6-nitro-phenyl ester methyl ester
[00240] To a stirring mixture of carbonic acid 2,4-di-tert-butyl-phenyl ester methyl ester (4.76 g, 180 mmol) in conc. sulfuric acid (2 mL), cooled in an ice-water bath, was added a cooled mixture of sulfuric acid (2 mL) and nitric acid (2 mL). The addition was done slowly so that the reaction temperature did not exceed 50 °C. The reaction was allowed to stir for 2 h while warming to room temperature. The reaction mixture was then added to ice-water and extracted into diethyl ether. The ether layer was dried (MgSO<com:Sub>4< / com:Sub>), concentrated and purified by column chromatography <com:Math><semantics>(0−10%)<annotation encoding="application / x-tex">(0 - 10\%)< / annotation>< / semantics>< / com:Math> ethyl acetate - hexanes) to yield a mixture of carbonic acid 2,4-di-tert-butyl-5-nitro-phenyl ester methyl ester and carbonic acid 2,4-di-tert-butyl-6-nitro-phenyl ester methyl ester as a pale yellow solid (4.28 g), which was used directly in the next step.
[00241] Step 3: 2,4-Di-tert-butyl-5-nitro-phenol and 2,4-Di-tert-butyl-6-nitro- phenol
[00242] The mixture of carbonic acid 2,4-di-tert-butyl-5-nitro-phenyl ester methyl ester and carbonic acid 2,4-di-tert-butyl-6-nitro-phenyl ester methyl ester (4.2 g, 14.0 mmol) was dissolved in MeOH (65 mL) before KOH (2.0 g, 36 mmol) was added. The mixture was stirred at room temperature for 2 h. The reaction mixture was then made acidic (pH 2-3) by adding conc. HCl and partitioned between water and diethyl ether. The ether layer was dried (MgSO<com:Sub>4< / com:Sub>), concentrated and purified by column chromatography <com:Math><semantics>(0−5%)<annotation encoding="application / x-tex">(0-5\%)< / annotation>< / semantics>< / com:Math> ethyl acetate – hexanes) to provide 2,4-di-tert-butyl-5-nitro- phenol (1.31 g, 29% over 2 steps) and 2,4-di-tert-butyl-6-nitro-phenol. 2,4-Di-tert- butyl-5-nitro-phenol: <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) δ 10.14 (s, 1H, OH), 7.34 (s, 1H), 6.83 (s, 1H), 1.36 (s, 9H), 1.30 (s, 9H). 2,4-Di-tert-butyl-6-nitro-phenol: <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 11.48 (s, 1H), 7.98 (d, J = 2.5 Hz, 1H), 7.66 (d, J = 2.4 Hz, 1H), 1.47 (s, 9H), 1.34 (s, 9H).
[00243] Step 4: 5-Amino-2,4-di-tert-butyl-phenol
[00244] To a refluxing solution of 2,4-di-tert-butyl-5-nitro-phenol (1.86 g, 7.40 mmol) and ammonium formate (1.86 g) in ethanol (75 mL) was added Pd-5% wt. on activated carbon (900 mg). The reaction mixture was stirred at reflux for 2 h, cooled to room temperature and filtered through Celite. The Celite was washed with methanol and the combined filtrates were concentrated to yield 5-amino-2,4-di-tert-butyl-phenol as a grey solid (1.66 g, quant.). <com:Math><semantics>1<annotation encoding="application / x-tex">{}^{1}< / annotation>< / semantics>< / com:Math>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.64 (s, 1H, OH), 6.84 (s, 1H), 6.08 (s, 1H), 4.39 (s, 2H, NH<com:Sub>2< / com:Sub>), 1.27 (m, 18H); HPLC ret. time 2.72 min, 10-99 % <com:Math><semantics>CH3CN<annotation encoding="application / x-tex">CH_3CN< / annotation>< / semantics>< / com:Math>, 5 min run; ESI-MS 222.4 m / z <com:Math><semantics>[M+H]+<annotation encoding="application / x-tex">[M+H]^+< / annotation>< / semantics>< / com:Math>.
[00245] Step 5: N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3- carboxamide [Image disponible dans le document PDF, Image available in the PDF document]
[00246] To a suspension of 4-oxo-1,4-dihydroquinolin-3-carboxylic acid (35.5 g, 188 mmol) and HBTU (85.7 g, 226 mmol) in DMF (280 mL) was added Et<com:Sub>3< / com:Sub>N (63.0 mL, 451 mmol) at ambient temperature. The mixture became homogeneous and was allowed to stir for 10 min before 5-amino-2,4-di-tert-butyl-phenol (50.0 g, 226 mmol) was added in small portions. The mixture was allowed to stir overnight at ambient temperature. The mixture became heterogeneous over the course of the reaction. After all of the acid was consumed (LC-MS analysis, MH+ 190, 1.71 min), the solvent was removed in vacuo. EtOH (ethyl alcohol) was added to the orange solid material to produce a slurry. The mixture was stirred on a rotovap (bath temperature 65 °C) for 15 min without placing the system under vacuum. The mixture was filtered and the captured solid was washed with hexanes to provide a white solid that was the EtOH crystalate. Et<com:Sub>2< / com:Sub>O (diethyl ether) was added to the solid obtained above until a slurry was formed. The mixture was stirred on a rotovapor (bath temperature 25 °C) for 15 min without placing the system under vacuum. The mixture was filtered and the solid captured. This procedure was performed a total of five times. The solid obtained after the fifth precipitation was placed under vacuum overnight to provide N-(5-hydroxy-2,4-di-tert- butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (38 g, 52%). HPLC ret. time 3.45 min, 10-99% CH<com:Sub>3< / com:Sub>CN, 5 min run; <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) δ 12.88 (s, 1H), 11.83 <com:Math><semantics>(s,1H),9.20(s,1H),8.87(s,1H),8.33(dd,J=8.2,1.0Hz,1H),7.83−7.79(m,1H),<annotation encoding="application / x-tex">(s, 1H), 9.20 (s, 1H), 8.87 (s, 1H), 8.33 (dd, J = 8.2, 1.0 Hz, 1H), 7.83-7.79 (m, 1H),< / annotation>< / semantics>< / com:Math> <com:Math><semantics>7.76<annotation encoding="application / x-tex">7.76< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.7<annotation encoding="application / x-tex">J = 7.7< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>7.54−7.50<annotation encoding="application / x-tex">7.54-7.50< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>7.17<annotation encoding="application / x-tex">7.17< / annotation>< / semantics>< / com:Math> (s, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>7.10<annotation encoding="application / x-tex">7.10< / annotation>< / semantics>< / com:Math> (s, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>1.38<annotation encoding="application / x-tex">1.38< / annotation>< / semantics>< / com:Math> (s, <com:Math><semantics>9H<annotation encoding="application / x-tex">9H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>1.37<annotation encoding="application / x-tex">1.37< / annotation>< / semantics>< / com:Math> (s, 9H); ESI-MS m / z calc'd 392.21; found 393.3 [M+H]<com:Sup>+< / com:Sup>.
[00247] Synthesis of Compound IV: 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
[00248] Compound IV may be prepared by coupling an acid chloride moiety with an amine moiety according to Schemes IV-A through IV-D. Scheme IV-A. Synthesis of the acid chloride moiety. [Image disponible dans le document PDF, Image available in the PDF document]
[00249] Scheme IV-A depicts the preparation of 1-(2,2-difluorobenzo[d][1,3]dioxol- 5-yl)cyclopropanecarbonyl chloride, which is used in Scheme IV-C to make the amide linkage of Compound IV.
[00250] The starting material, 2,2-difluorobenzo[d][1,3]dioxole-5-carboxylic acid, is commercially available from Saltigo (an affiliate of the Lanxess Corporation). Reduction of the carboxylc acid moiety in 2,2-difluorobenzo[d][1,3]dioxole-5- carboxylic acid to the primary alcohol, followed by conversion to the corresponding chloride using thionyl chloride (SOCl<com:Sub>2< / com:Sub>), provides 5-(chloromethyl)-2,2- difluorobenzo[d][1,3]dioxole, which is subsequently converted to 2-(2,2- difluorobenzo[d][1,3]dioxol-5-yl)acetonitrile using sodium cyanide. Treatment of 2- (2,2-difluorobenzo[d][1,3]dioxol-5-yl)acetonitrile with base and 1-bromo-2- chloroethane provides 1-(2,2-difluorobenzo[d][1,3]dioxol-5- yl)cyclopropanecarbonitrile. The nitrile moiety in 1-(2,2-difluorobenzo[d][1,3]dioxol- 5-yl)cyclopropanecarbonitrile is converted to a carboxylic acid using base to give 1- (2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxylic acid, which is converted to the desired acid chloride using thionyl chloride. Scheme IV-B. Alternative synthesis of the acid chloride moiety. [Image disponible dans le document PDF, Image available in the PDF document]
[00251] Scheme IV-B depicts an alternative synthesis of the requisite acid chloride. 5-bromomethyl-2,2-difluoro-1,3-benzodioxole is coupled with ethyl cyanoacetate in the presence of a palladium catalyst to form the corresponding alpha cyano ethyl ester. Saponification of the ester moiety to the carboxylic acid gives the cyanoethyl Compound IV. Alkylation of the cyanoethyl compound with 1-bromo-2-chloro ethane in the presence of base gives the cyanocyclopropyl compound. Treatment of the cyanocyclopropyl compound with base gives the carboxylate salt, which is converted to the carboxylic acid by treatment with acid. Conversion of the carboxylic acid to the acid chloride is then accomplished using a chlorinating agent such as thionyl chloride or the like. Scheme IV-C. Synthesis of the amine moiety. [Image disponible dans le document PDF, Image available in the PDF document]
[00252] Scheme IV-C depicts the preparation of the requisite tert-butyl 3-(6-amino-3- methylpyridin-2-yl)benzoate, which is coupled with 1-(2,2-difluorobenzo[d][1,3]dioxol- 5-yl)cyclopropanecarbonyl chloride in Scheme IV-C to give Compound IV. Palladium- catalyzed coupling of 2-bromo-3-methylpyridine with 3-(tert- butoxycarbonyl)phenylboronic acid gives tert-butyl 3-(3-methylpyridin-2-yl)benzoate, which is subsequently converted to the desired compound. Scheme IV-D. Formation of an acid salt of 3-(6-(1-(2,2- difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2- yl)benzoic acid. [Image disponible dans le document PDF, Image available in the PDF document]
[00253] Scheme IV-D depicts the coupling of 1-(2,2-difluorobenzo[d][1,3]dioxol-5- yl)cyclopropanecarbonyl chloride with tert-butyl 3-(6-amino-3-methylpyridin-2- yl)benzoate using triethyl amine and 4-dimethylaminopyridine to initially provide the tert-butyl ester of Compound IV.
[00254] Syntheses of Compounds
[00255] Synthesis of Compound 1
[00256] Part A: Synthesis of (4S)-2,2,4-trimethylpyrrolidine hydrochloride [Image disponible dans le document PDF, Image available in the PDF document]
[00257] Step 1: methyl-2,4-dimethyl-4-nitro-pentanoate [Image disponible dans le document PDF, Image available in the PDF document]
[00258] Tetrahydrofuran (THF, 4.5 L) was added to a 20 L glass reactor and stirred under N<com:Sub>2< / com:Sub> at room temperature. 2-Nitropropane (1.5 kg, 16.83 mol) and 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) (1.282 kg, 8.42 mol) were then charged to the reactor, and the jacket temperature was increased to 50 °C. Once the reactor contents were close to 50 °C, methyl methacrylate (1.854 kg, 18.52 mol) was added slowly over 100 minutes. The reaction temperature was maintained at or close to 50 °C for 21 hours. The reaction mixture was concentrated in vacuo then transferred back to the reactor and diluted with methyl tert-butyl ether (MTBE) (14 L). 2 M HCl (7.5 L) was added, and this mixture was stirred for 5 minutes then allowed to settle. Two clear layers were visible – a lower yellow aqueous phase and an upper green organic phase. The aqueous layer was removed, and the organic layer was stirred again with 2 M HCl (3 L). After separation, the HCl washes were recombined and stirred with MTBE (3 L) for 5 minutes. The aqueous layer was removed, and all of the organic layers were combined in the reactor and stirred with water (3 L) for 5 minutes. After separation, the organic layers were concentrated in vacuo to afford a cloudy green oil. Crude product was treated with MgSO<com:Sub>4< / com:Sub> and filtered to afford methyl-2,4-dimethyl-4-nitro-pentanoate as a clear green oil (3.16 kg, 99% yield).
[00259] <com:Sup>1< / com:Sup>H NMR (400 MHz, Chloroform-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 3.68 (s, 3H), 2.56 – 2.35 (m, 2H), 2.11 <com:Math><semantics>−2.00<annotation encoding="application / x-tex">-2.00< / annotation>< / semantics>< / com:Math> (m, 1H), 1.57 (s, 3H), 1.55 (s, 3H), 1.19 (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 3H).
[00260] Step 2: Synthesis of methyl (2S)-2,4-dimethyl-4-nitro-pentanoate [Image disponible dans le document PDF, Image available in the PDF document]
[00261] A reactor was charged with purified water (2090 L; 10 vol) and then potassium phosphate monobasic (27 kg, 198.4 moles; 13 g / L for water charge). The pH of the reactor contents was adjusted to pH 6.5 (<com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2) with 20% (w / v) potassium carbonate solution. The reactor was charged with racemic methyl-2,4-dimethyl-4-nitro- pentanoate (209 kg; 1104.6 moles), and Palatase 20000L lipase (13 L, 15.8 kg; 0.06 vol).
[00262] The reaction mixture was adjusted to <com:Math><semantics>32±2<annotation encoding="application / x-tex">32 \pm 2< / annotation>< / semantics>< / com:Math> °C and stirred for 15-21 hours, and pH 6.5 was maintained using a pH stat with the automatic addition of 20% potassium carbonate solution. When the racemic starting material was converted to >98% ee of the S-enantiomer, as determined by chiral GC, external heating was switched off. The reactor was then charged with MTBE (35 L; 5 vol), and the aqueous layer was extracted with MTBE (3 times, 400-1000L). The combined organic extracts were washed with aqueous Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (4 times, 522 L, 18 % w / w 2.5 vol), water (523 L; 2.5 vol), and 10% aqueous NaCl (314 L, 1.5 vol). The organic layer was concentrated in vacuo to afford methyl (2S)-2,4-dimethyl-4-nitro-pentanoate as a mobile yellow oil (>98% ee, 94.4 kg; 45 % yield).
[00263] Step 3: Synthesis of (3S)-3,5,5-trimethylpyrrolidin-2-one [Image disponible dans le document PDF, Image available in the PDF document]
[00264] A 20 L reactor was purged with <com:Math><semantics>N2<annotation encoding="application / x-tex">N_2< / annotation>< / semantics>< / com:Math>. The vessel was charged sequentially with DI water-rinsed, damp Raney® Ni (2800 grade, 250 g), methyl (2S)-2,4-dimethyl-4- nitro-pentanoate (1741g, 9.2 mol), and ethanol (13.9 L, 8 vol). The reaction was stirred at 900 rpm, and the reactor was flushed with <com:Math><semantics>H2<annotation encoding="application / x-tex">H_2< / annotation>< / semantics>< / com:Math> and maintained at <com:Math><semantics>∼2.5<annotation encoding="application / x-tex">\sim 2.5< / annotation>< / semantics>< / com:Math> bar. The reaction mixture was then warmed to 60 °C for 5 hours. The reaction mixture was cooled and filtered to remove Raney nickel, and the solid cake was rinsed with ethanol (3.5 L, 2 vol). The ethanolic solution of the product was combined with a second equal sized batch and concentrated in vacuo to reduce to a minimum volume of ethanol (~1.5 volumes). Heptane (2.5 L) was added, and the suspension was concentrated again to ~1.5 volumes. This was repeated 3 times; the resulting suspension was cooled to 0-5 °C, filtered under suction, and washed with heptane (2.5 L). The product was dried under vacuum for 20 minutes then transferred to drying trays and dried in a vacuum oven at 40 °C overnight to afford (3S)-3,5,5-trimethylpyrrolidin-2-one as a white crystalline solid (2.042 kg, 16.1 mol, 87 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, Chloroform-d) δ 6.39 (s, 1H), 2.62 <com:Math><semantics>(ddq,J=9.9,8.6,7.1Hz,1H),2.17(dd,J=12.4,8.6Hz,1H),1.56(dd,J=12.5,9.9)<annotation encoding="application / x-tex">(ddq, J = 9.9, 8.6, 7.1 Hz, 1H), 2.17 (dd, J = 12.4, 8.6 Hz, 1H), 1.56 (dd, J = 12.5, 9.9)< / annotation>< / semantics>< / com:Math> Hz, 1H), 1.31 (s, 3H), 1.25 (s, 3H), 1.20 (d, <com:Math><semantics>J=7.1 Hz<annotation encoding="application / x-tex">J = 7.1 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 3H).
[00265] Step 4: Synthesis of (4S)-2,2,4-trimethylpyrrolidine hydrochloride [Image disponible dans le document PDF, Image available in the PDF document]
[00266] A glass lined 120 L reactor was charged with lithium aluminum hydride pellets (2.5 kg, 66 mol) and dry THF (60 L) and warmed to 30 °C. The resulting suspension was charged with (S)-3,5,5-trimethylpyrrolidin-2-one (7.0 kg, 54 mol) in THF (25 L) over 2 hours while maintaining the reaction temperature at 30 to 40 °C. After complete addition, the reaction temperature was increased to 60 - 63 °C and maintained overnight. The reaction mixture was cooled to 22 °C, then cautiously quenched with the addition of ethyl acetate (EtOAc) (1.0 L, 10 moles), followed by a mixture of THF (3.4 L) and water (2.5 kg, 2.0 eq), and then a mixture of water (1.75 kg) with 50 % aqueous sodium hydroxide (750 g, 2 equiv water with 1.4 equiv sodium hydroxide relative to aluminum), followed by 7.5 L water. After the addition was complete, the reaction mixture was cooled to room temperature, and the solid was removed by filtration and washed with THF (3 x 25 L). The filtrate and washings were combined and treated with 5.0 L (58 moles) of aqueous 37% HCl (1.05 equiv.) while maintaining the temperature below 30°C. The resultant solution was concentrated by vacuum distillation to a slurry. Isopropanol (8 L) was added and the solution was concentrated to near dryness by vacuum distillation. Isopropanol (4 L) was added, and the product was slurried by warming to about 50 °C. MTBE (6 L) was added, and the slurry was cooled to 2-5 °C. The product was collected by filtration and rinsed with 12 L MTBE and dried in a vacuum oven (55 °C / 300 torr / N<com:Sub>2< / com:Sub> bleed) to afford (4S)-2,2,4- trimethylpyrrolidine•HCl as a white, crystalline solid (6.21 kg, 75% yield). <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400 MHz,DMSO-d6)δ9.34 (br d,2H),3.33 (dd,J=11.4,8.4 Hz,1H),2.75 (dd,J=11.4,8.4 Hz,1H)<annotation encoding="application / x-tex">(400 \text{ MHz}, \text{DMSO-}d6) \delta 9.34 \text{ (br d}, 2\text{H)}, 3.33 \text{ (dd}, J = 11.4, 8.4 \text{ Hz}, 1\text{H)}, 2.75 \text{ (dd}, J = 11.4, 8.4 \text{ Hz}, 1\text{H)}< / annotation>< / semantics>< / com:Math> 11.4, 8.6 Hz, 1H), <com:Math><semantics>2.50−2.39<annotation encoding="application / x-tex">2.50 - 2.39< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.97<annotation encoding="application / x-tex">1.97< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=12.7<annotation encoding="application / x-tex">J = 12.7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.7<annotation encoding="application / x-tex">7.7< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>1.42<annotation encoding="application / x-tex">1.42< / annotation>< / semantics>< / com:Math> (s, 3H), 1.38 (dd, <com:Math><semantics>J=12.8<annotation encoding="application / x-tex">J = 12.8< / annotation>< / semantics>< / com:Math>, 10.1 Hz, 1H), 1.31 (s, 3H), 1.05 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H).
[00267] Part B: Preparation of <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>-(1,3-dimethylpyrazol-4-yl)sulfonyl-6-[3-(3,3,3- trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1- yl|pyridine-3-carboxamide (Compound 1) [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]
[00268] Preparation of starting materials:
[00269] 3,3,3-Trifluoro-2,2-dimethyl-propan-1-ol [Image disponible dans le document PDF, Image available in the PDF document]
[00270] A 1 L 3 neck round bottom flask was fitted with a mechanical stirrer, a cooling bath, an addition funnel, and a J-Kem temperature probe. The vessel was charged with lithium aluminum hydride (LAH) pellets (6.3 g, 0.1665 mol) under a nitrogen atmosphere. The vessel was then charged with tetrahydrofuran (200 mL) under a nitrogen atmosphere. The mixture was allowed to stir at room temperature for 0.5 hours to allow the pellets to dissolve. The cooling bath was then charged with crushed ice in water and the reaction temperature was lowered to 0 °C. The addition funnel was charged with a solution of 3,3,3-trifluoro-2,2-dimethyl-propanoic acid (20 g, 0.1281 mol) in tetrahydrofuran (60 mL) and the clear pale yellow solution was added drop wise over 1 hour. After the addition was complete the mixture was allowed to slowly warm to room temperature and stirring was continued for 24 hours. The suspension was cooled to 0 °C with a crushed ice-water in the cooling bath and then quenched by the very slow and drop wise addition of water (6.3 ml), followed by sodium hydroxide solution (15 weight %; 6.3 mL) and then finally with water (18.9 mL). The reaction temperature of the resulting white suspension was recorded at 5 °C. The suspension was stirred at ~5 °C for 30 minutes and then filtered through a 20 mm layer of Celite. The filter cake was washed with tetrahydrofuran (2 x 100 mL). The filtrate was dried over sodium sulfate (150 g) and then filtered. The filtrate was concentrated under reduced pressure to provide a clear colorless oil (15 g) containing a mixture of the product 3,3,3- trifluoro-2,2-dimethyl-propan-1-ol in THF (73 % weight of product ~10.95g, and 27 wt.% THF as determined by 1H-NMR). The distillate from the rotary evaporation was distilled at atmospheric pressure using a 30 cm Vigreux column to provide 8.75 g of a residue containing 60 % weight of THF and 40 % weight of product (~3.5 g). The estimated total amount of product is 14.45 g (79% yield). 1H NMR (400 MHz, DMSO- d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 4.99 (t, J = 5.7 Hz, 1H), 3.38 (dd, J = 5.8, 0.9 Hz, 2H), 1.04 (d, J = 0.9 Hz, 6H).
[00271] tert-Butyl 3-oxo-2,3-dihydro-1H-pyrazole-1-carboxylate [Image disponible dans le document PDF, Image available in the PDF document]
[00272] A 50L Syrris controlled reactor was started and jacket set to 20 °C, stirring at 150 rpm, reflux condenser (10 °C) and nitrogen purge. MeOH (2.860 L) and methyl (E)-3-methoxyprop-2-enoate (2.643 kg, 22.76 mol) were added and the reactor was capped. The reaction was heated to an internal temperature of 40 °C and the system was set to hold jacket temp at 40 °C. Hydrazine hydrate (1300 g of 55 %w / w, 22.31 mol) was added portion wise via addition funnel over 30 min. The reaction was heated to 60 °C for 1 h. The reaction mixture was cooled to 20 °C and triethyamine (2.483 kg, 3.420 L, 24.54 mol) was added portion wise (exothermic), maintaining reaction temp <30 °C. A solution of Boc anhydride (di-tert-butyl dicarbonate) (4.967 kg, 5.228 L, 22.76 mol) in MeOH (2.860 L) was added portion wise maintaining temperature <45 °C. The reaction mixture was stirred at 20 °C for 16 h. The reaction solution was partially concentrated to remove MeOH, resulting in a clear light amber oil. The resulting oil was transferred to the 50L reactor, stirred and added water (7.150 L) and heptane (7.150 L). The additions caused a small amount of the product to precipitate. The aqueous layer was drained into a clean container and the interface and heptane layer were filtered to separate the solid (product). The aqueous layer was transferred back to the reactor, and the collected solid was placed back into the reactor and mixed with the aqueous layer. A dropping funnel was added to the reactor and loaded with acetic acid (1.474 kg, 1.396 L, 24.54 mol), then began dropwise addition of acid. The jacket was set to 0 °C to absorb the quench exotherm. After addition (pH=5), the reaction mixture was stirred for 1 h. The solid was collected by filtration and washed with water (7.150 L), and washed a second time with water (3.575 L) and pulled dry. The crystalline solid was scooped out of the filter into a 20L rotovap bulb and heptane (7.150 L) was added. The mixture was slurried at 45 °C for 30 mins, and then distilled off 1-2 volumes of solvent. The slurry in the rotovap flask was filtered and the solids washed with heptane (3.575 L) and pulled dry. The solid was further dried in vacuo (50 °C, 15 mbar) to give tert-butyl 5-oxo-1H- pyrazole-2-carboxylate (2921 g, 71%) as coarse, crystalline solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 10.95 (s, 1H), 7.98 (d, <com:Math><semantics>J=2.9<annotation encoding="application / x-tex">J = 2.9< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.90 (d, <com:Math><semantics>J=2.9<annotation encoding="application / x-tex">J = 2.9< / annotation>< / semantics>< / com:Math> Hz, 1H), 1.54 (s, 9H).
[00273] Step A: tert-Butyl 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazole-1- carboxylate [Image disponible dans le document PDF, Image available in the PDF document]
[00274] A mixture of 3,3,3-trifluoro-2,2-dimethyl-propan-1-ol (10 g, 70.36 mmol) and tert-butyl 3-hydroxypyrazole-1-carboxylate (12.96 g, 70.36 mmol) in toluene (130 mL) was treated with triphenyl phosphine (20.30 g, 77.40 mmol) followed by isopropyl N-isopropoxycarbonyliminocarbamate (14.99 mL, 77.40 mmol) and the mixture was stirred at 110 °C for 16 hours. The yellow solution was concentrated under reduced pressure, diluted with heptane (100mL) and the precipitated triphenylphosphine oxide was removed by filtration and washed with heptane / toluene 4:1 (100mL). The yellow filtrate was evaporated and the residue purified by silica gel chromatography with a linear gradient of ethyl acetate in hexane (0-40%) to give tert-butyl 3-(3,3,3-trifluoro- 2,2-dimethyl-propoxy)pyrazole-1-carboxylate (12.3 g, 57%) as an off white solid. ESI- MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 308.13477, found 309.0 (M+1) +; Retention time: 1.84 minutes. <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400 MHz, DMSO-d6)δ8.10(d,J=3.0 Hz,1H),6.15(d,J=3.0 Hz,1H),4.18(s,2H),<annotation encoding="application / x-tex">(400 \text{ MHz}, \text{ DMSO-d6}) \delta 8.10 (d, J = 3.0 \text{ Hz}, 1\text{H}), 6.15 (d, J = 3.0 \text{ Hz}, 1\text{H}), 4.18 (s, 2\text{H}),< / annotation>< / semantics>< / com:Math> 1.55 (s, 9H), 1.21 (s, 6H).
[00275] Step B: 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole [Image disponible dans le document PDF, Image available in the PDF document]
[00276] tert-Butyl 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazole-1-carboxylate (13.5 g, 43.79 mmol) was treated with 4 M hydrogen chloride in dioxane (54.75 mL, 219.0 mmol) and the mixture was stirred at 45 °C for 1 hour. The reaction mixture was evaporated to dryness and the residue was extracted with 1 M aqueous NaOH (100ml) and methyl tert-butyl ether (100ml), washed with brine (50ml) and extracted with methyl tert-butyl ether (50ml). The combined organic phases were dried, filtered and evaporated to give 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole (9.0 g, 96%) as an off white waxy solid. ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 208.08235, found 209.0 (M+1) <com:Math><semantics>+<annotation encoding="application / x-tex">^+< / annotation>< / semantics>< / com:Math>; Retention time: 1.22 minutes. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) δ 11.91 (s, 1H), 7.52 (d, <com:Math><semantics>J=2.2 Hz<annotation encoding="application / x-tex">J = 2.2 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 1H), 5.69 (t, <com:Math><semantics>J=2.3 Hz<annotation encoding="application / x-tex">J = 2.3 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 1H), 4.06 (s, 2H), 1.19 (s, 6H).
[00277] Step C: tert-Butyl 2,6-dichloropyridine-3-carboxylate [Image disponible dans le document PDF, Image available in the PDF document]
[00278] A solution of 2,6-dichloropyridine-3-carboxylic acid (10 g, 52.08 mmol) in THF (210 mL) was treated successively with di-tert-butyl dicarbonate (17 g, 77.89) mmol) and 4-(dimethylamino)pyridine (3.2 g, 26.19 mmol) and left to stir overnight at room temperature. At this point, HCl 1N (400 mL) was added and the mixture was stirred vigorously for about 10 minutes. The product was extracted with ethyl acetate (2x300mL) and the combined organics layers were washed with water (300 mL) and brine (150 mL) and dried over sodium sulfate and concentrated under reduced pressure to give 12.94 g (96% yield) of tert-butyl 2,6-dichloropyridine-3-carboxylate as a colorless oil. ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 247.01668, found 248.1 (M+1) +; Retention time: 2.27 minutes. <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>) ppm 1.60 (s, 9H), 7.30 (d, J=7.9 Hz, 1H), 8.05 (d, <com:Math><semantics>J=8.2 Hz,1H<annotation encoding="application / x-tex">J=8.2 \text{ Hz}, 1\text{H}< / annotation>< / semantics>< / com:Math>).
[00279] Step D: tert-Butyl 2-chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl- propoxy)pyrazol-1-yl]pyridine-3-carboxylate [Image disponible dans le document PDF, Image available in the PDF document]
[00280] To a solution of tert-butyl 2,6-dichloropyridine-3-carboxylate (10.4 g, 41.9 mmol) and 3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)-1H-pyrazole (9.0 g, 41.93 mmol) in DMF (110 mL) were added potassium carbonate (7.53 g, 54.5 mmol) and 1,4- diazabicyclo[2.2.2]octane (706 mg, 6.29 mmol) and he mixture was stirred at room temperature for 16 hours. The cream suspension was cooled in a cold water bath and cold water (130 mL) was slowly added. The thick suspension was stirred at room temperature for 1 hour, filtered and washed with plenty of water to give tert-butyl 2- chloro-6-[3-(3,3,3-trifluoro-2,2-dimethyl-propoxy)pyrazol-1-yl]pyridine-3-carboxylate <com:Math><semantics>(17.6 g,99%)<annotation encoding="application / x-tex">(17.6 \text{ g}, 99\%)< / annotation>< / semantics>< / com:Math> as an off white solid. ESI-MS <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math> calc. 419.12234, found 420.0 (M+1) <com:Math><semantics>+<annotation encoding="application / x-tex">^+< / annotation>< / semantics>< / com:Math>; Retention time: 2.36 minutes. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.44 (d, J = 2.9 Hz, 1H), <com:Math><semantics>8.31<annotation encoding="application / x-tex">8.31< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>7.76<annotation encoding="application / x-tex">7.76< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.26<annotation encoding="application / x-tex">6.26< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=2.9<annotation encoding="application / x-tex">J = 2.9< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.27<annotation encoding="application / x-tex">4.27< / annotation>< / semantics>< / com:Math> (s, 2H), 1.57 (s, 9H), 1.24 (s, 6H). [...
Claims
CLAIMS:
1. A compound having a formula chosen from any one of the following formulae: Compound 1 Compound 9 Compound 13 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Compound 14 Compound 15 Compound 28 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing.
2. A compound according to claim 1 having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] a deuterated derivative thereof, or a pharmaceutically acceptable salt of the compound or deuterated derivative thereof.
3. A compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] • 4. A pharmaceutically acceptable salt of a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] ٠ 5. A pharmaceutical composition comprising: (a) a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] (b) a pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition further comprises Compound II: [Image disponible dans le document PDF, Image available in the PDF document] • 7. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition further comprises Compound III: [Image disponible dans le document PDF, Image available in the PDF document] , 8. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition further comprises Compound III: [Image disponible dans le document PDF, Image available in the PDF document] , 9. A pharmaceutical composition comprising: (a) a pharmaceutically acceptable salt of a compound having the following formula: [Image disponible dans le document PDF, Image available in the PDF document] (b) a pharmaceutically acceptable carrier.
10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition further comprises Compound II: [Image disponible dans le document PDF, Image available in the PDF document] • 11. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition further comprises Compound III: [Image disponible dans le document PDF, Image available in the PDF document] ٠ 12. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition further comprises Compound III: [Image disponible dans le document PDF, Image available in the PDF document] .
13. Use of the compound as defined in claim 3 for treating cystic fibrosis.
14. Use of the pharmaceutically acceptable salt as defined in claim 4 for treating cystic fibrosis.
15. Use of a pharmaceutical composition as defined in any one of claims 5 to 8 for treating cystic fibrosis.
16. Use of a pharmaceutical composition as defined in any one of claims 9 to 12 for treating cystic fibrosis.
17. A method of preparing a compound of Formula (X): [Image disponible dans le document PDF, Image available in the PDF document] , a deuterated derivative thereof, or a pharmaceutically acceptable salt of the compound or the deuterated derivative, comprising reacting a compound of Formula (F) or a salt thereof with a compound of Formula (G), a deuterated derivative thereof, or a salt of the compound or the deuterated derivative to generate said compound of Formula (X), a deuterated derivative thereof, or a pharmaceutically acceptable salt of the compound or the deuterated derivative: [Image disponible dans le document PDF, Image available in the PDF document] wherein in each of said formulae: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - each <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more hydroxy groups, or optionally two geminal <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math>, together with the carbon atom to which they are attached, form a C<com:Sub>3-4< / com:Sub> cycloalkyl; - each <com:Math><semantics>ℝ4<annotation encoding="application / x-tex">\mathbb{R}^4< / annotation>< / semantics>< / com:Math> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, halogenated <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups, and halogens; - X<com:Sup>a< / com:Sup> is F or Cl; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; - p is 0, 1, or 2; and - q is 0, 1, 2, 3, 4, 5, 6, 7, or 8.
18. The method of claim 17, wherein each <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N; and each <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> is CH.
19. The method of claim 17 or 18, wherein said reacting a compound of Formula (F) or a salt thereof with a compound of Formula (G), a deuterated derivative thereof, or a salt of the compound or the deuterated derivative is performed in the presence of a base.
20. The method of any one of claims 17-19, wherein a salt of the compound of Formula (G) is employed.
21. The method of claim 20, wherein said salt of the compound of Formula (G) is a HCl salt of the compound of Formula (G).
22. A method of preparing a compound of Formula (F) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , comprising reacting a compound of Formula (D) or a salt thereof with a compound of Formula (E) or a salt thereof to generate a compound of Formula (F) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , wherein in each of said formulae: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; [Image disponible dans le document PDF, Image available in the PDF document] - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - each <com:Math><semantics>ℝ4<annotation encoding="application / x-tex">\mathbb{R}^4< / annotation>< / semantics>< / com:Math> is independently chosen from halogens; - <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen and <com:Math><semantics>ℂ1<annotation encoding="application / x-tex">\mathbb{C}_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>ℂ4<annotation encoding="application / x-tex">\mathbb{C}_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - X<com:Sup>a< / com:Sup> is F or Cl; - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; and - p is 0, 1, or 2.
23. The method of claim 22, wherein <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N; and <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> is CH.
24. The method of claim 22 or 23, wherein said reacting a compound of Formula (D) or a salt thereof with a compound of Formula (E) or a salt thereof is performed in the presence of a base.
25. The method of claim 22 or 23, wherein said reacting a compound of Formula (D) or a salt thereof with a compound of Formula (E), or a salt thereof comprises reacting a compound of Formula (D) with a coupling reagent and subsequently with a compound of Formula (E) in the presence of a base.
26. A method of preparing a compound of the following formula: [Image disponible dans le document PDF, Image available in the PDF document] (Compound 1) a deuterated derivative thereof, or a pharmaceutically acceptable salt of the compound or the deuterated derivative, comprising reacting a compound of Formula (F-1) or a salt thereof, with a compound of Formula (G-1), a deuterated derivative thereof, or a salt of the compound or the deuterated derivative to generate said Compound 1, a deuterated derivative thereof, or a pharmaceutically acceptable salt of the compound or the deuterated derivative: [Image disponible dans le document PDF, Image available in the PDF document] wherein X<com:Sup>a< / com:Sup> in Formula (F-1) is F or Cl.
27. The method of claim 26, wherein said reacting a compound of Formula (F-1) or a salt thereof with a compound of Formula (G-1), a deuterated derivative thereof, or a salt of the compound or the deuterated derivative is performed in the presence of a base.
28. The method of claim 26 or 27, wherein a salt of the compound of Formula (G-1) is employed.
29. The method of claim 28, wherein said salt of the compound of Formula (G-1) is a HCl salt of the compound of Formula (G-1).
30. A method of preparing a compound of Formula (F-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] (F-1) , comprising reacting a compound of Formula (D-1) or a salt thereof and a compound of Formula (E-1) or a salt thereof to generate a compound of Formula (F-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] , wherein in each said formulae, X<com:Sup>a< / com:Sup> is F or Cl.
31. The method of claim 30, wherein said reacting a compound of Formula (D-1) or a salt thereof with a compound of Formula (E-1) or a salt thereof is performed in the presence of a base.
32. The method of claim 30, wherein said reacting a compound of Formula (D-1) or a salt thereof with a compound of Formula (E-1) or a salt thereof comprises reacting a compound of Formula (D-1) with a coupling reagent and subsequently with a compound of Formula (E-1) in the presence of a base.
33. A method of preparing a compound of Formula (D-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] (D-1) , comprising: (i) reacting a compound of Formula (A-1) or a salt thereof and a compound of Formula (B-1) or a salt thereof to generate a compound of Formula (C-1) or a salt thereof: [Image disponible dans le document PDF, Image available in the PDF document] ; and (ii) hydrolyzing the -C(O)OR<com:Sup>a< / com:Sup> group of a compound of Formula (C-1) or a salt thereof to generate a compound of Formula (D-1) or a salt thereof, wherein in each said formulae, each R<com:Sup>a< / com:Sup> is independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl; and X<com:Sup>a< / com:Sup> is independently F or Cl.
34. The method of claim 33, wherein the hydrolysis of the –C(O)OR<com:Sup>a< / com:Sup> group is performed in the presence of a base or acid.
35. The method of claim 33 or 34, wherein said reacting a compound of Formula (A-1) or a salt thereof and a compound of Formula (B-1) or a salt thereof is performed in the presence of a base.
36. The method of any one of claims 33-35, wherein R<com:Sup>a< / com:Sup> is ethyl or t-butyl.
37. A compound of Formula (F): [Image disponible dans le document PDF, Image available in the PDF document] , a deuterated derivative thereof, or a salt of the compound or deuterated derivative thereof, wherein: - one of <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N and the other is CH; - <com:Math><semantics>𝑹1<annotation encoding="application / x-tex">\mathbf{R}^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−(𝑪(𝑹2)< / mo>2)k<annotation encoding="application / x-tex">-(\mathbf{C}(\mathbf{R}^2)_2)_k< / annotation>< / semantics>< / com:Math>-O-<com:Math><semantics>(𝑪(𝑹2)2)m𝑹7<annotation encoding="application / x-tex">(\mathbf{C}(\mathbf{R}^2)_2)_m\mathbf{R}^7< / annotation>< / semantics>< / com:Math>, - each <com:Math><semantics>ℝ2<annotation encoding="application / x-tex">\mathbb{R}^2< / annotation>< / semantics>< / com:Math> is independently chosen from hydrogen; halogens; cyano; hydroxy; <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups; and C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens, hydroxy, and C<com:Sub>3-5< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - each <com:Math><semantics>ℝ4<annotation encoding="application / x-tex">\mathbb{R}^4< / annotation>< / semantics>< / com:Math> is independently chosen from halogens; - <com:Math><semantics>𝑹5<annotation encoding="application / x-tex">\mathbf{R}^5< / annotation>< / semantics>< / com:Math> is chosen from hydrogen and <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl groups; - each <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> is chosen from halogens, cyano, hydroxy, hydroxymethyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkoxy groups, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups; - <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chosen from hydrogen, halogens, cyano, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math> alkyl groups optionally substituted with one or more substituents each independently chosen from halogens and hydroxy, and C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub> cycloalkyl groups optionally substituted with one or more substituents each independently chosen from C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, halogenated C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub> alkyl groups, and halogens; - X<com:Sup>a< / com:Sup> is F or Cl - k is 0 or 1; - r is 0 or 1; - m is 0, 1, 2, or 3; and - p is 0, 1, or 2.
38. A compound according to claim 37, a deuterated derivative thereof, or a salt of the compound or deuterated derivative thereof, wherein <com:Math><semantics>Y2<annotation encoding="application / x-tex">Y^2< / annotation>< / semantics>< / com:Math> is N; and each <com:Math><semantics>Y1<annotation encoding="application / x-tex">Y^1< / annotation>< / semantics>< / com:Math> is CH.
39. A compound of Formula (F-1): [Image disponible dans le document PDF, Image available in the PDF document] (F-1) , a deuterated derivative thereof, or a salt of the compound or deuterated derivative thereof, wherein X<com:Sup>a< / com:Sup> is F or Cl.
40. A compound of Formula (C-1) or (D-1): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(C−1)<annotation encoding="application / x-tex">(C-1)< / annotation>< / semantics>< / com:Math> or (D-1) , a deuterated derivative thereof, or a salt of any of the foregoing, wherein R<com:Sup>a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl; and each X<com:Sup>a< / com:Sup> is independently F or Cl.
41. A compound according to claim 40, a deuterated derivative thereof, or a salt of the compound or deuterated derivative thereof, wherein R<com:Sup>a< / com:Sup> is ethyl or t-butyl.
42. A compound of Formula (A-1), (C-1) or (D-1): [Image disponible dans le document PDF, Image available in the PDF document] , a deuterated derivative thereof, or a salt of any of the foregoing, wherein R<com:Sup>a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl; and each X<com:Sup>a< / com:Sup> is independently F or Cl.
43. Crystalline Form A of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>6.6±0.2<annotation encoding="application / x-tex">6.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.6±0.2<annotation encoding="application / x-tex">7.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9.6±0.2<annotation encoding="application / x-tex">9.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.4±0.2<annotation encoding="application / x-tex">12.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4±0.2<annotation encoding="application / x-tex">16.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math> 0.2, and <com:Math><semantics>18.6±0.2<annotation encoding="application / x-tex">18.6 \pm 0.2< / annotation>< / semantics>< / com:Math>.
44. Crystalline Form A according to claim 43, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>6.6±0.2<annotation encoding="application / x-tex">6.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9.6±0.2<annotation encoding="application / x-tex">9.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.6±0.2<annotation encoding="application / x-tex">18.6 \pm 0.2< / annotation>< / semantics>< / com:Math>.
45. Crystalline Form A according to claim 43, characterized by an X-ray powder diffractogram having a signal at three two-theta values of <com:Math><semantics>6.6±0.2<annotation encoding="application / x-tex">6.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math>.
46. Crystalline Form A according to claim 43, characterized by an X-ray powder diffractogram having a signal at six two-theta values of <com:Math><semantics>6.6±0.2<annotation encoding="application / x-tex">6.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9.6±0.2<annotation encoding="application / x-tex">9.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>18.2±0.2<annotation encoding="application / x-tex">18.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.6±0.2<annotation encoding="application / x-tex">18.6 \pm 0.2< / annotation>< / semantics>< / com:Math>.
47. A Compound 1 solvate: [Image disponible dans le document PDF, Image available in the PDF document] chosen from methanol solvates, ethanol solvates, 1-propanol solvates, 2-propanol solvates, acetic acid solvates, toluene solvates, sulfolane solvates, propionic acid solvates, methyl tert-butyl ether solvates, isobutyric acid solvates, anisole solvates, methylbutyl ketone solvates, and xylene solvates of Compound 1.
48. The Compound 1 solvate according to claim 47, chosen from methanol solvates, ethanol solvates, 1-propanol solvates, and 2-propanol solvates of Compound 1.
49. Crystalline Form M of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] • • characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.7±0.2<annotation encoding="application / x-tex">13.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.9±0.2<annotation encoding="application / x-tex">15.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4±0.2<annotation encoding="application / x-tex">16.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8<annotation encoding="application / x-tex">17.8< / annotation>< / semantics>< / com:Math> <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, and 19.3 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.
2.
50. Crystalline Form M according to claim 49, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±<annotation encoding="application / x-tex">13.1 \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2,13.7±0.2,15.2±0.2,17.8±0.2,<annotation encoding="application / x-tex">0.2, 13.7 \pm 0.2, 15.2 \pm 0.2, 17.8 \pm 0.2,< / annotation>< / semantics>< / com:Math>and <com:Math><semantics>19.3±0.2.<annotation encoding="application / x-tex">19.3 \pm 0.2.< / annotation>< / semantics>< / com:Math> 51. Crystalline Form M according to claim 49, characterized by an X-ray powder diffractogram having a signal at three two-theta values of <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>.
52. Crystalline Form M according to claim 49, characterized by an X-ray powder diffractogram having a signal at six two-theta values of <com:Math><semantics>11.6±0.2<annotation encoding="application / x-tex">11.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.1±0.2<annotation encoding="application / x-tex">13.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.7±0.2<annotation encoding="application / x-tex">13.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.2±0.2<annotation encoding="application / x-tex">15.2 \pm 0.2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>19.3±0.2<annotation encoding="application / x-tex">19.3 \pm 0.2< / annotation>< / semantics>< / com:Math>.
53. Crystalline Form E of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] ノ characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.2±0.2<annotation encoding="application / x-tex">11.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.1±0.2<annotation encoding="application / x-tex">14.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.1±0.2<annotation encoding="application / x-tex">15.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±0.2<annotation encoding="application / x-tex">16.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>17.8<annotation encoding="application / x-tex">17.8< / annotation>< / semantics>< / com:Math> <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, and 18.9 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.
2.
54. Crystalline Form E according to claim 53, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>11.2±0.2<annotation encoding="application / x-tex">11.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±<annotation encoding="application / x-tex">12.8 \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.1±0.2<annotation encoding="application / x-tex">15.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±0.2<annotation encoding="application / x-tex">16.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>.
55. Crystalline Form E according to claim 53, characterized by an X-ray powder diffractogram having a signal at three two-theta values of <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±0.2<annotation encoding="application / x-tex">16.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>.
56. Crystalline Form E according to claim 53, characterized by an X-ray powder diffractogram having a signal at six two-theta values of <com:Math><semantics>11.2±0.2<annotation encoding="application / x-tex">11.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.1±<annotation encoding="application / x-tex">15.1 \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.1±0.2<annotation encoding="application / x-tex">16.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.8±0.2<annotation encoding="application / x-tex">17.8 \pm 0.2< / annotation>< / semantics>< / com:Math>.
57. A crystalline Form X of a potassium salt of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 1, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>4.9±0.2<annotation encoding="application / x-tex">4.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9±0.2<annotation encoding="application / x-tex">5.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.1±0.2<annotation encoding="application / x-tex">8.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.5±0.2<annotation encoding="application / x-tex">8.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>10.3±0.2<annotation encoding="application / x-tex">10.3 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.0±0.2<annotation encoding="application / x-tex">13.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.9±0.2<annotation encoding="application / x-tex">13.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.6±0.2<annotation encoding="application / x-tex">14.6 \pm 0.2< / annotation>< / semantics>< / com:Math> 0.2, and <com:Math><semantics>17.0±0.2<annotation encoding="application / x-tex">17.0 \pm 0.2< / annotation>< / semantics>< / com:Math>.
58. Crystalline Form X according to claim 57, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>4.9±0.2<annotation encoding="application / x-tex">4.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9±0.2<annotation encoding="application / x-tex">5.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.1±0.2<annotation encoding="application / x-tex">8.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.0±0.2<annotation encoding="application / x-tex">13.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.9±0.2<annotation encoding="application / x-tex">13.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.0±0.2<annotation encoding="application / x-tex">17.0 \pm 0.2< / annotation>< / semantics>< / com:Math>.
59. Crystalline Form X according to claim 57, characterized by an X-ray powder diffractogram having a signal at three two-theta values of <com:Math><semantics>4.9±0.2<annotation encoding="application / x-tex">4.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9±0.2<annotation encoding="application / x-tex">5.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>13.0±0.2<annotation encoding="application / x-tex">13.0 \pm 0.2< / annotation>< / semantics>< / com:Math>.
60. Crystalline Form X according to claim 57, characterized by an X-ray powder diffractogram having a signal at six two-theta values of <com:Math><semantics>4.9±0.2<annotation encoding="application / x-tex">4.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9±0.2<annotation encoding="application / x-tex">5.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.1±0.2<annotation encoding="application / x-tex">8.1 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.0±0.2<annotation encoding="application / x-tex">13.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.9±0.2<annotation encoding="application / x-tex">13.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.0±0.2<annotation encoding="application / x-tex">17.0 \pm 0.2< / annotation>< / semantics>< / com:Math>.
61. A crystalline Form Y of a sodium salt of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] 1, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>3.5±0.2<annotation encoding="application / x-tex">3.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.8±0.2<annotation encoding="application / x-tex">12.8 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.2±0.2<annotation encoding="application / x-tex">14.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.4±0.2<annotation encoding="application / x-tex">15.4 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.6±0.2<annotation encoding="application / x-tex">16.6 \pm 0.2< / annotation>< / semantics>< / com:Math> 0.2, and <com:Math><semantics>18.0±0.2<annotation encoding="application / x-tex">18.0 \pm 0.2< / annotation>< / semantics>< / com:Math>.
62. Crystalline Form Y according to claim 61, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>3.5±0.2<annotation encoding="application / x-tex">3.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.2±0.2<annotation encoding="application / x-tex">14.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.0±0.2<annotation encoding="application / x-tex">18.0 \pm 0.2< / annotation>< / semantics>< / com:Math>.
63. Crystalline Form Y according to claim 61, characterized by an X-ray powder diffractogram having a signal at three two-theta values of <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math>.
64. Crystalline Form Y according to claim 61, characterized by an X-ray powder diffractogram having a signal at six two-theta values of <com:Math><semantics>3.5±0.2<annotation encoding="application / x-tex">3.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.0±0.2<annotation encoding="application / x-tex">7.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>11.7±0.2<annotation encoding="application / x-tex">11.7 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>13.2±0.2<annotation encoding="application / x-tex">13.2 \pm 0.2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>14.2±0.2<annotation encoding="application / x-tex">14.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>18.0±0.2<annotation encoding="application / x-tex">18.0 \pm 0.2< / annotation>< / semantics>< / com:Math>.
65. A solid dispersion comprising Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] and a polymer.
66. The solid dispersion of claim 65, wherein the solid dispersion comprises 50 wt% of Compound 1 and 50 wt% of the polymer by the total weight of the solid dispersion or 80 wt% of Compound 1 and 20 wt% of the polymer by the total weight of the solid dispersion.
67. The solid dispersion of claim 65 or 66, wherein the polymer is a hypromellose acetate succinate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, or Polyvinylpyrrolidone.
68. A pharmaceutical composition comprising at least one crystalline form according to any one of claims 43-46 and 49-64, or at least one solvate according to claim 47 or 48, and a pharmaceutically acceptable carrier.
69. Use of at least one crystalline form as defined in any one of claims 43-46 and 49-64, or at least one solvate according to claim 47 or 48 for treating cystic fibrosis in a patient in need thereof.
70. Use of a solid dispersion as defined in any one of claims 65-67 for treating cystic fibrosis in a patient in need thereof.
71. Crystalline Form P2 of Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] , characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>10.2±0.2<annotation encoding="application / x-tex">10.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±0.2<annotation encoding="application / x-tex">12.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.9±0.2<annotation encoding="application / x-tex">12.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.0±0.2<annotation encoding="application / x-tex">15.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.9±0.2<annotation encoding="application / x-tex">15.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.2±0.2<annotation encoding="application / x-tex">16.2 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.5±0.2<annotation encoding="application / x-tex">16.5 \pm 0.2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2, and 17.6 <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.
2.
72. Crystalline Form P2 according to claim 71, characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±<annotation encoding="application / x-tex">12.6 \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.9±0.2<annotation encoding="application / x-tex">12.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.0±0.2<annotation encoding="application / x-tex">15.0 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.5±0.2<annotation encoding="application / x-tex">16.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.6±0.2<annotation encoding="application / x-tex">17.6 \pm 0.2< / annotation>< / semantics>< / com:Math>.
73. Crystalline Form P2 according to claim 71, characterized by an X-ray powder diffractogram having a signal at three two-theta values of <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±0.2<annotation encoding="application / x-tex">12.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.6±0.2<annotation encoding="application / x-tex">17.6 \pm 0.2< / annotation>< / semantics>< / com:Math>.
74. Crystalline Form P2 according to claim 71, characterized by an X-ray powder diffractogram having a signal at six two-theta values of <com:Math><semantics>10.9±0.2<annotation encoding="application / x-tex">10.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.6±0.2<annotation encoding="application / x-tex">12.6 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>12.9±0.2<annotation encoding="application / x-tex">12.9 \pm 0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>15.0±<annotation encoding="application / x-tex">15.0 \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2<annotation encoding="application / x-tex">0.2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.5±0.2<annotation encoding="application / x-tex">16.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>17.6±0.2<annotation encoding="application / x-tex">17.6 \pm 0.2< / annotation>< / semantics>< / com:Math>.
Citation Information
Patent Citations
Deuterated CFTR potentiators
US8865902B2
